1
|
Gupta P, Zhan PL, Leeds I, Mongiu A, Reddy V, Pantel HJ. Practice Patterns and Trends in the Surgical Management of Mismatch Repair Deficient Colon Cancer. J Surg Res 2024; 304:371-382. [PMID: 39615154 DOI: 10.1016/j.jss.2024.10.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2024] [Revised: 10/11/2024] [Accepted: 10/26/2024] [Indexed: 12/15/2024]
Abstract
INTRODUCTION Defects in the DNA mismatch repair (MMR) pathway can predispose individuals to colorectal cancer (CRC), with germline mutations in this pathway leading to Lynch syndrome. Consequently, universal MMR testing is recommended for all newly diagnosed CRC patients to detect mismatch repair deficient (MMR-D) tumors, enabling informed treatment decisions. Given the increased potential for metachronous disease in patients with Lynch syndrome, the current guidelines for surgical management of Lynch-associated colon cancer recommend extended resection in patients under age 60. METHODS A retrospective analysis of nonmetastatic CRC was performed from the National Cancer Database to evaluate the current trends and practice patterns in the surgical management of MMR-D colon cancer, as well as assess the factors influencing choice of surgical procedure. RESULTS From 2018 to 2020, 98,112 nonmetastatic CRC patients were identified, with 19.93% being MMR-D. MMR-D colon cancer patients were more likely to undergo extended resection than those with mismatch repair proficient tumors (9.4% versus 4.2%, P < 0.001). When accounting for approximately one-fourth of MMR-D colon cancers being attributable to Lynch syndrome, the frequency of extended resection was less than expected (9.4% versus 25%, P < 0.001). MMR-D patients under age 60 were more likely to undergo extended resection than those over age 60 (9% versus 3%) (odds ratio [OR] 3.57, 95% confidence interval [CI] 3.06-4.15). Several factors were associated with decreased rate of extended resection: uninsured (OR 0.42, 95% CI 0.21-0.84), Black race (OR 0.54, 95% CI 0.35-0.82), treatment at nonacademic centers (OR 0.74, 95% CI 0.56-0.97), and crowfly distance >25 miles (OR 1.98, 95% CI 1.14-3.45). CONCLUSIONS These findings provide valuable insight into the current surgical practice patterns in the management of MMR-D colon cancers and possibly colon cancers associated with Lynch syndrome.
Collapse
Affiliation(s)
- Princy Gupta
- Division of Colon and Rectal Surgery, Yale School of Medicine, New Haven, Connecticut.
| | - Peter L Zhan
- Division of General Surgery, Yale School of Medicine, New Haven, Connecticut
| | - Ira Leeds
- Division of Colon and Rectal Surgery, Yale School of Medicine, New Haven, Connecticut
| | - Anne Mongiu
- Division of Colon and Rectal Surgery, Yale School of Medicine, New Haven, Connecticut
| | - Vikram Reddy
- Division of Colon and Rectal Surgery, Yale School of Medicine, New Haven, Connecticut
| | - Haddon J Pantel
- Division of Colon and Rectal Surgery, Yale School of Medicine, New Haven, Connecticut
| |
Collapse
|
2
|
Frank A, Bernstedt SW, Jamizadeh N, Forsberg A, Hedin C, Blom J, Backman AS. Complications of colonoscopy surveillance of patients with Lynch syndrome - 33 years of follow up. Fam Cancer 2024; 23:599-605. [PMID: 39102097 PMCID: PMC11512902 DOI: 10.1007/s10689-024-00416-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/06/2024]
Abstract
BACKGROUND AND STUDY AIMS Lynch syndrome (LS) is a hereditary autosomal dominant condition, with an increased lifetime risk of developing malignancies including colorectal cancer (CRC). Current guidelines differ in recommended colonoscopy-surveillance intervals from 1 to 2 years. Although colonoscopy is considered a safe procedure, there are risks of severe adverse events (SAEs), such as perforation and bleeding, as well as adverse events (AEs), such as abdominal discomfort and post-colonoscopy gastrointestinal infections. Colonoscopy-related bleeding and perforation rates have been reported 0.17% and 0.11%, respectively. However, there are insufficient data regarding complications of colonoscopy-surveillance for LS patients. This study aims to investigate the risk of AEs among LS patients during colonoscopy in the Stockholm region. PATIENTS AND METHODS This retrospective cohort study includes 351 LS patients undergoing endoscopic surveillance at the Karolinska University Hospital, August 1989 - April 2021. Data from endoscopic surveillance colonoscopies were extracted from patients' medical records. RESULTS Of 1873 endoscopies in 351 LS patients, 12 complications (AEs) were documented within 30 days (0.64%) and with a total of 3 bleedings (SAEs, 0.16%). No perforations were identified. CONCLUSION Colonoscopy surveillance for LS patients shows a comparatively low risk of AEs per-examination. Colonoscopy complications per-patient, including both SAEs and AEs, show a significantly higher risk. Colonoscopy complications only including SAEs, show a comparatively low risk. Understanding the lifetime risk of surveillance-related colonoscopy complications is important when designing targeted surveillance programmes.
Collapse
Affiliation(s)
- Alexander Frank
- Dept. of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Gastroenterology unit, Dept. of Medicine, Capio S:t Görans Hospital, Stockholm, Sweden.
| | - Sophie Walton Bernstedt
- Dept. of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
- Gastroenterology unit, Dept. of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden
- Div. of Upper Gastrointestinal diseases, Karolinska University Hospital, Stockholm, Sweden
| | - Nigin Jamizadeh
- Dept. of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
| | - Anna Forsberg
- Gastroenterology unit, Dept. of Medicine, Capio S:t Görans Hospital, Stockholm, Sweden
- Dept. of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden
| | - Charlotte Hedin
- Gastroenterology unit, Dept. of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden
- Dept. of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden
| | - Johannes Blom
- Dept. of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden
- Dept. of Surgery, Södersjukhuset, Stockholm, Sweden
| | - Ann-Sofie Backman
- Dept. of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
- Gastroenterology unit, Dept. of Medicine, Ersta Hospital, Stockholm, Sweden
| |
Collapse
|
3
|
Jessiman-Perreault G, Law J, Adhikari K, Machado AA, Moysey B, Xu L, Yang H, Scott LKA, Teare G, Li A. Geospatial analysis and participant characteristics associated with colorectal cancer screening participation in Alberta, Canada: a population-based cross-sectional study. BMC Health Serv Res 2023; 23:1454. [PMID: 38129826 PMCID: PMC10740253 DOI: 10.1186/s12913-023-10486-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 12/16/2023] [Indexed: 12/23/2023] Open
Abstract
BACKGROUND Colorectal cancer (CRC) is a leading cause of death in Canada and early detection can prevent deaths through screening. However, CRC screening in Alberta, Canada remains suboptimal and varies by sociodemographic and health system characteristics, as well as geographic location. This study aimed to further the understanding of these participant and health system characteristics associated with CRC screening in Alberta and identify clusters of regions with higher rates of overdue or unscreened individuals. METHODS We included Albertans aged 52 to 74 as of December 31, 2019 (index date) and we used data from administrative health data sources and linked to the Alberta Colorectal Cancer Screening Program database to determine colorectal cancer screening rates. We used multivariable multinomial logistic regression analysis to investigate the relationship between sociodemographic, health system characteristics and participation in CRC screening. We used optimized Getis-Ord Gi* hot-spot analysis to identify hot and cold-spots in overdue for and no record of CRC screening. RESULTS We included 919,939 Albertans, of which 65% were currently up to date on their CRC screening, 21% were overdue, and 14% had no record of CRC screening. Compared to Albertans who were currently up to date, those who were in older age groups, those without a usual provider of care, those who were health system non-users, and those living in more deprived areas were more likely to have no record of screening. Areas with high number of Albertans with no record of screening were concentrated in the North and Central zones. CONCLUSIONS Our study showed important variation in colorectal cancer screening participation across sociodemographic, health system and geographical characteristics and identified areas with higher proportions of individuals who have no record of screening or are under-screened in Alberta, Canada.
Collapse
Affiliation(s)
- Geneviève Jessiman-Perreault
- Provincial Population and Public Health, Alberta Health Services, Holy Cross Centre, 2210 2 St SW, Calgary, AB, T2S 3C3, Canada
| | - Jessica Law
- Provincial Population and Public Health, Alberta Health Services, Holy Cross Centre, 2210 2 St SW, Calgary, AB, T2S 3C3, Canada
| | - Kamala Adhikari
- Provincial Population and Public Health, Alberta Health Services, Holy Cross Centre, 2210 2 St SW, Calgary, AB, T2S 3C3, Canada.
- Department of Community Health Sciences, University of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada.
| | - Amanda Alberga Machado
- Provincial Population and Public Health, Alberta Health Services, Holy Cross Centre, 2210 2 St SW, Calgary, AB, T2S 3C3, Canada
| | - Barbara Moysey
- Screening Programs, Provincial Population and Public Health, Alberta Health Services, Holy Cross Centre, 2210 2 St SW, Calgary, AB, T2S 3C3, Canada
| | - Linan Xu
- Screening Programs, Provincial Population and Public Health, Alberta Health Services, Holy Cross Centre, 2210 2 St SW, Calgary, AB, T2S 3C3, Canada
| | - Huiming Yang
- Department of Community Health Sciences, University of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada
- Screening Programs, Provincial Population and Public Health, Alberta Health Services, Holy Cross Centre, 2210 2 St SW, Calgary, AB, T2S 3C3, Canada
| | - Lisa K Allen Scott
- Provincial Population and Public Health, Alberta Health Services, Holy Cross Centre, 2210 2 St SW, Calgary, AB, T2S 3C3, Canada
- Department of Community Health Sciences, University of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada
- Department of Oncology, University of Calgary, 1331 29th Street NW, Calgary, AB, T2N 4N2, Canada
| | - Gary Teare
- Provincial Population and Public Health, Alberta Health Services, Holy Cross Centre, 2210 2 St SW, Calgary, AB, T2S 3C3, Canada
- Department of Community Health Sciences, University of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada
| | - Alvin Li
- Provincial Population and Public Health, Alberta Health Services, Holy Cross Centre, 2210 2 St SW, Calgary, AB, T2S 3C3, Canada
| |
Collapse
|
4
|
Macrae F. Balancing the burden and benefits of colonoscopy in Lynch Syndrome. Fam Cancer 2023; 22:399-401. [PMID: 37713026 DOI: 10.1007/s10689-023-00347-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/12/2023] [Indexed: 09/16/2023]
Affiliation(s)
- Finlay Macrae
- Department of Colorectal Medicine and Genetics, The Royal Melbourne Hospital, and Dept of Medicine, University of Melbourne, Melbourne, Australia, PO Box 2010 Royal Melbourne Hospital, 3050, Melbourne, Victoria, Australia.
| |
Collapse
|
5
|
van Liere ELSA, Jacobs IL, Dekker E, Jacobs MAJM, de Boer NKH, Ramsoekh D. Colonoscopy surveillance in Lynch syndrome is burdensome and frequently delayed. Fam Cancer 2023; 22:403-411. [PMID: 37171677 PMCID: PMC10176312 DOI: 10.1007/s10689-023-00333-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Accepted: 04/18/2023] [Indexed: 05/13/2023]
Abstract
Individuals with Lynch syndrome have an increased colorectal cancer risk, hence, biennial colonoscopy surveillance is recommended. We aimed to investigate patients' perception and preferences regarding surveillance, and to further explore compliance behaviour. Individuals with Lynch syndrome received a validated survey evaluating experiences of their three most recent colonoscopies. Individuals were non-compliant to surveillance if the interval between colonoscopies differed ≥ 6 months from the recommended interval. In total, 197 of 291 (68%) invited individuals returned the survey. They mostly underwent colonoscopy biennially (99%), under mild sedation (79%) and with bowel preparation performed by Moviprep® (99%). Surveillance was perceived as impacting quality of life in 21%, and as moderately to extremely burdensome in 57%, particularly in those below age 40. To lower the burden, patients prioritised improvements in volume and taste of bowel preparation, laxation-related bowel movements, waiting times, and a more personal and respectful approach of endoscopic staff. Additionally, many individuals (60%) would favour less-invasive surveillance modalities such as biomarkers. In total, 28% of individuals had delayed colonoscopy surveillance, predominantly for patient-related reasons. An additional 10% considered quitting/postponing surveillance. Upon multivariable analysis, patient-related delay was associated with low and medium education, history of ≤ 4 colonoscopies and having no hospital recall-system. Colonoscopy surveillance in Lynch syndrome is often experienced as burdensome, and frequently delayed. We identified determinants of surveillance behaviour in this population, and present potential interventions to reduce the burden and non-compliance rates.
Collapse
Affiliation(s)
- Elsa L S A van Liere
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
- Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam, The Netherlands.
- School of Medicine, Vrije Universiteit, Amsterdam, The Netherlands.
| | - Imke L Jacobs
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands
- School of Medicine, Vrije Universiteit, Amsterdam, The Netherlands
| | - Evelien Dekker
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Center location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - Maarten A J M Jacobs
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands
| | - Nanne K H de Boer
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands
- Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam, The Netherlands
- School of Medicine, Vrije Universiteit, Amsterdam, The Netherlands
| | - Dewkoemar Ramsoekh
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands
- Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam, The Netherlands
- School of Medicine, Vrije Universiteit, Amsterdam, The Netherlands
| |
Collapse
|
6
|
Erdaği Oral S, Özer N. Body Image Perception and the Effect of Different Educational Programs on Embarrassment in Patients Undergoing Colonoscopy. J Perianesth Nurs 2023; 38:76-82. [PMID: 35953402 DOI: 10.1016/j.jopan.2022.05.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 04/20/2022] [Accepted: 05/13/2022] [Indexed: 01/28/2023]
Abstract
PURPOSE Colonoscopy is recognized as a safe and effective tool for detecting colorectal cancer. However, patients may experience discomfort and embarrassment arising from their body image, with the prejudice that health care professionals will have negative thoughts about their bodies. This study was carried out to determine the effect of the perception of body image and education given with different educational programs on the feeling of embarrassment in patients who were scheduled to undergo colonoscopy. DESIGN Quasi-experimental study with pre-test, post-test. METHODS The population of this quasi -experimental study with pre-test, post-test, and experimental groups consisted of 184 patients who underwent colonoscopy for the first time at the endoscopy department of a university hospital. FINDINGS No statistically significant difference in the mean Colonoscopy Embarrassment Scale (CES) pre-test scores was found between the groups (P > .05). The mean CES post-test scores of the video group were lower than those of the other groups, with a statistically significant difference (P < .05). Comparing the intragroup CES pre-test and post-test mean scores, the mean CES post-test scores were found to be lower in all three groups, with a statistically significant difference between the groups (P < .05). Although a statistically weak negative correlation was found between the body image mean scores and the pre-test CES mean scores of the booklet and video groups, no correlation was observed in the control group. CONCLUSIONS The body image perception was found to affect the sense of embarrassment in patients undergoing colonoscopy, and the mean embarrassment scores decreased with planned training programs.
Collapse
Affiliation(s)
- Semra Erdaği Oral
- Kafkas University, Faculty of Health Sciences, Surgical Nursing Department, Kars, Turkey.
| | - Nadiye Özer
- Atatürk University, Faculty of Nursing, Surgical Nursing Department, Erzurum, Turkey
| |
Collapse
|
7
|
Lincoln A, Benton S, Piggott C, North BV, Rigney J, Young C, Quirke P, Sasieni P, Monahan KJ. Exploring the utility and acceptability of Faecal immunochemical testing (FIT) as a novel intervention for the improvement of colorectal Cancer (CRC) surveillance in individuals with lynch syndrome (FIT for lynch study): a single-arm, prospective, multi-centre, non-randomised study. BMC Cancer 2022; 22:1144. [PMID: 36344941 PMCID: PMC9639321 DOI: 10.1186/s12885-022-10217-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 10/22/2022] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Lynch Syndrome (LS) is an inherited cancer predisposition syndrome defined by pathogenic variants in the mismatch repair (MMR) or EPCAM genes. In the United Kingdom, people with LS are advised to undergo biennial colonoscopy from as early as 25 until 75 years of age to mitigate a high lifetime colorectal cancer (CRC) risk, though the consideration of additional surveillance intervention(s) through the application of non-invasive diagnostic devices has yet to be longitudinally observed in LS patients. In this study, we will examine the role of annual faecal immunochemical testing (FIT) alongside biennial colonoscopy for CRC surveillance in people with LS. METHODS/DESIGN In this single-arm, prospective, non-randomised study, 400 LS patients will be recruited across 11 National Health Service (NHS) Trusts throughout the United Kingdom. Study inclusion requires a LS diagnosis, between 25 and 73 years old, and a routine surveillance colonoscopy scheduled during the recruitment period. Eligible patients will receive a baseline OC-Sensor™ FIT kit ahead of their colonoscopy, and annually for 3 years thereafter. A pre-paid envelope addressed to the central lab will be included within all patient mailings for the return of FIT kits and relevant study documents. A questionnaire assessing attitudes and perception of FIT will also be included at baseline. All study samples received by the central lab will be assayed on an OC-Sensor™ PLEDIA Analyser. Patients with FIT results of ≥6 μg of Haemoglobin per gram of faeces (f-Hb) at Years 1 and/or 3 will be referred for colonoscopy via an urgent colonoscopy triage pathway. 16S rRNA gene V4 amplicon sequencing will be carried out on residual faecal DNA of eligible archived FIT samples to characterise the faecal microbiome. DISCUSSION FIT may have clinical utility alongside colonoscopic surveillance in people with LS. We have designed a longitudinal study to examine the efficacy of FIT as a non-invasive modality. Potential limitations of this method will be assessed, including false negative or false positive FIT results related to specific morphological features of LS neoplasia or the presence of post-resection anastomotic inflammation. The potential for additional colonoscopies in a subset of participants may also impact on colonoscopic resources and patient acceptability. TRIAL REGISTRATION Trial Registration: ISRCTN, ISRCTN15740250 . Registered 13 July 2021.
Collapse
Affiliation(s)
- Anne Lincoln
- Comprehensive Cancer Centre, King's College London, London, UK
| | - Sally Benton
- NHS Bowel Cancer Screening South of England Hub, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK
| | - Carolyn Piggott
- NHS Bowel Cancer Screening South of England Hub, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK
| | - Bernard V North
- Comprehensive Cancer Centre, King's College London, London, UK
| | - Jane Rigney
- Comprehensive Cancer Centre, King's College London, London, UK
| | - Caroline Young
- Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK
| | - Philip Quirke
- Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK
| | - Peter Sasieni
- Comprehensive Cancer Centre, King's College London, London, UK
| | - Kevin J Monahan
- The Lynch Syndrome and Family Cancer Clinic, St Mark's Hospital and Academic Institute, Harrow, UK.
- Imperial College London, London, UK.
| |
Collapse
|
8
|
Kang YJ, Caruana M, McLoughlin K, Killen J, Simms K, Taylor N, Frayling IM, Coupé VMH, Boussioutas A, Trainer AH, Ward RL, Macrae F, Canfell K. The predicted effect and cost-effectiveness of tailoring colonoscopic surveillance according to mismatch repair gene in patients with Lynch syndrome. Genet Med 2022; 24:1831-1846. [PMID: 35809086 DOI: 10.1016/j.gim.2022.05.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 05/30/2022] [Accepted: 05/31/2022] [Indexed: 10/17/2022] Open
Abstract
PURPOSE Lynch syndrome-related colorectal cancer (CRC) risk substantially varies by mismatch repair (MMR) gene. We evaluated the health impact and cost-effectiveness of MMR gene-tailored colonoscopic surveillance. METHODS We first estimated sex- and MMR gene-specific cumulative lifetime risk of first CRC without colonoscopic surveillance using an optimization algorithm. Next, we harnessed these risk estimates in a microsimulation model, "Policy1-Lynch," and compared 126 colonoscopic surveillance strategies against no surveillance. RESULTS The most cost-effective strategy was 3-yearly surveillance from age 25 to 70 years (pathogenic variants [path_] in MLH1 [path_MLH1], path_MSH2) with delayed surveillance for path_MSH6 (age 30-70 years) and path_PMS2 (age 35-70 years) heterozygotes (incremental cost-effectiveness ratio = Australian dollars (A) $8,833/life-year saved). This strategy averted 60 CRC deaths (153 colonoscopies per death averted) over the lifetime of 1000 confirmed patients with Lynch syndrome (vs no surveillance). This also reduced colonoscopies by 5% without substantial change in health outcomes (vs nontailored 3-yearly surveillance from 25-70 years). Generally, starting surveillance at age 25 (vs 20) years was more cost-effective with minimal effect on life-years saved and starting 5 to 10 years later for path_MSH6 and path_PMS2 heterozygotes (vs path_MLH1 and path_MSH2) further improved cost-effectiveness. Surveillance end age (70/75/80 years) had a minor effect. Three-yearly surveillance strategies were more cost-effective (vs 1 or 2-yearly) but prevented 3 fewer CRC deaths. CONCLUSION MMR gene-specific colonoscopic surveillance would be effective and cost-effective.
Collapse
Affiliation(s)
- Yoon-Jung Kang
- The Daffodil Centre, The University of Sydney, A Joint Venture With Cancer Council NSW, Sydney, New South Wales, Australia.
| | - Michael Caruana
- The Daffodil Centre, The University of Sydney, A Joint Venture With Cancer Council NSW, Sydney, New South Wales, Australia
| | - Kirstie McLoughlin
- The Daffodil Centre, The University of Sydney, A Joint Venture With Cancer Council NSW, Sydney, New South Wales, Australia
| | - James Killen
- The Daffodil Centre, The University of Sydney, A Joint Venture With Cancer Council NSW, Sydney, New South Wales, Australia
| | - Kate Simms
- The Daffodil Centre, The University of Sydney, A Joint Venture With Cancer Council NSW, Sydney, New South Wales, Australia
| | - Natalie Taylor
- The Daffodil Centre, The University of Sydney, A Joint Venture With Cancer Council NSW, Sydney, New South Wales, Australia
| | - Ian M Frayling
- Inherited Tumour Syndromes Research Group, Cardiff University, Cardiff, Wales, United Kingdom
| | - Veerle M H Coupé
- Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | | | | | - Robyn L Ward
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Finlay Macrae
- Colorectal Medicine & Genetics, The Royal Melbourne Hospital, Parkville, Victoria, Australia
| | - Karen Canfell
- The Daffodil Centre, The University of Sydney, A Joint Venture With Cancer Council NSW, Sydney, New South Wales, Australia
| |
Collapse
|
9
|
van Liere ELSA, de Boer NKH, Dekker E, van Leerdam ME, de Meij TGJ, Ramsoekh D. Systematic review: non-endoscopic surveillance for colorectal neoplasia in individuals with Lynch syndrome. Aliment Pharmacol Ther 2022; 55:778-788. [PMID: 35181895 PMCID: PMC9303645 DOI: 10.1111/apt.16824] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 12/08/2021] [Accepted: 02/02/2022] [Indexed: 12/09/2022]
Abstract
BACKGROUND Individuals with Lynch syndrome are at high risk for colorectal cancer (CRC). Regular colonoscopies have proven to decrease CRC incidence and mortality. However, colonoscopy is burdensome and interval CRCs still occur. Hence, an accurate, less-invasive screening method that guides the timing of colonoscopy would be of important value. AIM To outline the performance of non-endoscopic screening modalities for Lynch-associated CRC and adenomas. METHODS Systematic literature search in MEDLINE and EMBASE to identify studies investigating imaging techniques and biomarkers for detection of CRC and adenomas in Lynch syndrome. The QUADAS-2 tool was used for the quality assessment of included studies. RESULTS Seven of 1332 screened articles fulfilled the inclusion criteria. Two studies evaluated either CT colonography or MR colonography; both techniques were unable to detect CRC and (advanced) adenomas <10 mm. The other five studies evaluated plasma methylated-SEPTIN9, faecal immunochemical test (FIT), faecal tumour DNA markers (BAT-26, hMLH1, p53, D9S171, APC, D9S162, IFNA and DCC) and faecal microbiome as screening modalities. Sensitivity for CRC varied from 33% (BAT-26) to 70% (methylated-SEPTIN9) to 91% (hMLH1). High specificity (94-100%) for CRC and/or adenomas was observed for methylated-SEPTIN9, FIT and BAT-26. Desulfovibrio was enriched in the stool of patients having adenomas. However, all these studies were characterised by small populations, high/unclear risk of bias and/or low prevalence of adenomas. CONCLUSIONS Imaging techniques are unsuitable for colon surveillance in Lynch syndrome, whereas biomarkers are understudied. Having outlined biomarker research in Lynch-associated and sporadic CRC/adenomas, we believe that these non-invasive markers may hold potential (whether or not combined) for this population. As they could be of great value, (pre-)clinical studies in this field should be prioritised.
Collapse
Affiliation(s)
- Elsa L. S. A. van Liere
- Department of Gastroenterology and HepatologyAmsterdam University Medical Centre, AGEM Research Institute, Vrije Universiteit AmsterdamAmsterdamThe Netherlands
| | - Nanne K. H. de Boer
- Department of Gastroenterology and HepatologyAmsterdam University Medical Centre, AGEM Research Institute, Vrije Universiteit AmsterdamAmsterdamThe Netherlands
| | - Evelien Dekker
- Department of Gastroenterology and HepatologyAmsterdam University Medical Centre, University of AmsterdamAmsterdamThe Netherlands
| | - Monique E. van Leerdam
- Department of GastroenterologyNetherlands Cancer InstituteAmsterdamThe Netherlands,Department of Gastroenterology and HepatologyLeiden University Medical CenterLeidenThe Netherlands
| | - Tim G. J. de Meij
- Department of Paediatric GastroenterologyEmma Children’s Hospital, Amsterdam University Medical Centre, Vrije Universiteit AmsterdamAmsterdamThe Netherlands
| | - Dewkoemar Ramsoekh
- Department of Gastroenterology and HepatologyAmsterdam University Medical Centre, Vrije Universiteit AmsterdamAmsterdamThe Netherlands
| |
Collapse
|
10
|
Lee J, Keil M, Lee JS, Baird A, Choi HY. Gender Effects on the Impact of Colorectal Cancer Risk Calculators on Screening Intentions: An Experimental Study (Preprint). JMIR Form Res 2022. [DOI: 10.2196/37553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
11
|
Nasri Nasrabadi P, Nayeri Z, Gharib E, Salmanipour R, Masoomi F, Mahjoubi F, Zomorodipour A. Establishment of a CALU, AURKA, and MCM2 gene panel for discrimination of metastasis from primary colon and lung cancers. PLoS One 2020; 15:e0233717. [PMID: 32469983 PMCID: PMC7259615 DOI: 10.1371/journal.pone.0233717] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Accepted: 05/11/2020] [Indexed: 12/15/2022] Open
Abstract
Metastasis is known as a key step in cancer recurrence and could be stimulated by multiple factors. Calumenin (CALU) is one of these factors which has a direct impact on cancer metastasis and yet, its underlined mechanisms have not been completely elucidated. The current study was aimed to identify CALU co-expressed genes, their signaling pathways, and expression status within the human cancers. To this point, CALU associated genes were visualized using the Cytoscape plugin BisoGenet and annotated with the Enrichr web-based application. The list of CALU related diseases was retrieved using the DisGenNet, and cancer datasets were downloaded from The Cancer Genome Atlas (TCGA) and analyzed with the Cufflink software. ROC curve analysis was used to estimate the diagnostic accuracy of DEGs in each cancer, and the Kaplan–Meier survival analysis was performed to plot the overall survival of patients. The protein level of the signature biomarkers was measured in 40 biopsy specimens and matched adjacent normal tissues collected from CRC and lung cancer patients. Analysis of CALU co-expressed genes network in TCGA datasets indicated that the network is markedly altered in human colon (COAD) and lung (LUAD) cancers. Diagnostic accuracy estimation of differentially expressed genes showed that a gene panel consisted of CALU, AURKA, and MCM2 was able to successfully distinguish cancer tumors from healthy samples. Cancer cases with abnormal expression of the signature genes had a significantly lower survival rate than other patients. Additionally, comparison of CALU, AURKA, and MCM2 proteins between healthy samples, early and advanced tumors showed that the level of these proteins was increased through normal–carcinoma transition in both types of cancers. These data indicate that the interactions between CALU, AURKA, and MCM2 has a pivotal role in cancer development, and thereby needs to be explored in the future.
Collapse
Affiliation(s)
- Parinaz Nasri Nasrabadi
- Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
| | - Zahra Nayeri
- Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
| | - Ehsan Gharib
- Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Reza Salmanipour
- Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
| | - Fatemeh Masoomi
- Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
| | - Forouzandeh Mahjoubi
- Department of Medical Genetics, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
| | - Alireza Zomorodipour
- Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
- * E-mail: ,
| |
Collapse
|
12
|
Goh LH, Spigelman AD. Assessing the adherence to guidelines in Lynch syndrome patients: a pilot study. ANZ J Surg 2020; 90:1130-1135. [PMID: 32039553 DOI: 10.1111/ans.15690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 12/26/2019] [Indexed: 11/30/2022]
Abstract
BACKGROUND Cancer surveillance is important in the management of Lynch syndrome. In New South Wales, management guidelines for Lynch syndrome are published on the eviQ website. Benefits of cancer surveillance are maximized through adherence to guidelines. This has yet to be investigated in Sydney. Hence, this study aimed to determine the adherence rate of patients to these guidelines, assess their knowledge of the guidelines and determine potential factors hindering regular colonoscopies in these patients. METHODS A cross-sectional study was conducted among Lynch syndrome patients from the St Vincent's Hospital Cancer Genetics Unit, Sydney. Patients who appropriately fulfilled our inclusion criteria were mailed a questionnaire. The questionnaire was mailed twice to increase the response rate. Demographic and medical information were collected from patient medical records. Patient responses were analysed to determine adherence to the guidelines. RESULTS Sixty-two individuals were invited to participate in this study. Among them, 47 responded (76%) with two being excluded, due to potential confounding factors. Thirty (67%) had their colonoscopies at recommended intervals, while 15 (33%) had delays. Within these two groups, many were ultimately deemed non-adherent to the guidelines due to over-screening with other tests. In total, 31 (69%) participants were considered over-screening for cancer, leaving only seven (16%) participants fully adherent to the guidelines. Only three (7%) had knowledge of the eviQ guidelines. CONCLUSIONS Adherence to the eviQ guidelines was poor. The majority of participants were being over-screened for cancer. Knowledge of the guidelines needs to be improved.
Collapse
Affiliation(s)
- Li-Han Goh
- Faculty of Medicine, St Vincent's Clinical School, The University of New South Wales, Sydney, New South Wales, Australia.,Cancer Genetics Unit, The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, New South Wales, Australia
| | - Allan D Spigelman
- Faculty of Medicine, St Vincent's Clinical School, The University of New South Wales, Sydney, New South Wales, Australia.,Cancer Genetics Unit, The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, New South Wales, Australia
| |
Collapse
|
13
|
Koloseni DN, Lee CY, Gan ML. Understanding Information Security Behaviours of Tanzanian Government Employees. INTERNATIONAL JOURNAL OF TECHNOLOGY AND HUMAN INTERACTION 2019. [DOI: 10.4018/ijthi.2019010102] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
This article investigates security behaviours of employees using the Health Belief Model (HBM) as a theoretical lens. Given the fact that previous studies on security behaviours paid much attention to conscious information security behaviours; this article extends the HBM to study both habitual or automatic security behaviours (security habit) and conscious security behaviours of Tanzanian government employees. A structural equation modelling (SEM) technique was used for data analysis. The study found that, the intentions of government employees to practice information security behaviour is influenced by perceived severity, perceived susceptibility, perceived barriers, and cues to action and security habits. Their intentions, however, is not affected by perceived benefits and self-efficacy. Further, an employee's intentions and security habits has a significant effect on actual security practice. Generally, the extended research model enriches the understanding of the role played by both conscious and habitual security behaviours on information security behaviours of employees.
Collapse
|
14
|
Pan JY, Haile RW, Templeton A, Macrae F, Qin F, Sundaram V, Ladabaum U. Worldwide Practice Patterns in Lynch Syndrome Diagnosis and Management, Based on Data From the International Mismatch Repair Consortium. Clin Gastroenterol Hepatol 2018; 16:1901-1910.e11. [PMID: 29702294 PMCID: PMC6440473 DOI: 10.1016/j.cgh.2018.04.025] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Revised: 03/22/2018] [Accepted: 04/08/2018] [Indexed: 02/07/2023]
Abstract
BACKGROUND & AIMS Families with a history of Lynch syndrome often do not adhere to guidelines for genetic testing and screening. We investigated practice patterns related to Lynch syndrome worldwide, to ascertain potential targets for research and public policy efforts. METHODS We collected data from the International Mismatch Repair Consortium (IMRC), which comprises major research and clinical groups engaged in the care of families with Lynch syndrome worldwide. IMRC institutions were invited to complete a questionnaire to characterize diagnoses of Lynch syndrome and management practice patterns. RESULTS Fifty-five providers, representing 63 of 128 member institutions (49%) in 21 countries, completed the questionnaire. For case finding, 55% of respondents reported participating in routine widespread population tumor testing among persons with newly diagnosed Lynch syndrome-associated cancers, whereas 27% reported relying on clinical criteria with selective tumor and/or germline analyses. Most respondents (64%) reported using multigene panels for germline analysis, and only 28% reported testing tumors for biallelic mutations for cases in which suspected pathogenic mutations were not confirmed by germline analysis. Respondents reported relying on passive dissemination of information to at-risk family members, and there was variation in follow through of genetic testing recommendations. Reported risk management practices varied-nearly all programs (98%) recommended colonoscopy every 1 to 2 years, but only 35% recommended chemoprevention with aspirin. CONCLUSIONS There is widespread heterogeneity in management practices for Lynch syndrome worldwide among IMRC member institutions. This may reflect the rapid pace of emerging technology, regional differences in resources, and the lack of definitive data for many clinical questions. Future efforts should focus on the large numbers of high-risk patients without access to state-of-the-art Lynch syndrome management.
Collapse
Affiliation(s)
- Jennifer Y Pan
- Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California; Division of Gastroenterology, Department of Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
| | - Robert W Haile
- Department of Medicine, Division of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, California
| | - Allyson Templeton
- International Mismatch Repair Consortium, Fred Hutchinson Cancer Research Center, Seattle, Washington
| | - Finlay Macrae
- Department of Medicine, University of Melbourne, Melbourne, Australia; Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Melbourne, Australia
| | - FeiFei Qin
- Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, California
| | - Vandana Sundaram
- Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, California
| | - Uri Ladabaum
- Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California
| |
Collapse
|
15
|
Steel E, Robbins A, Jenkins M, Flander L, Gaff C, Keogh L. How does genetic risk information for Lynch syndrome translate to risk management behaviours? Hered Cancer Clin Pract 2017; 15:1. [PMID: 28070225 PMCID: PMC5217251 DOI: 10.1186/s13053-016-0061-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Accepted: 12/09/2016] [Indexed: 01/16/2023] Open
Abstract
Background There is limited research on why some individuals who have undergone predictive genetic testing for Lynch syndrome do not adhere to screening recommendations. This study aimed to explore qualitatively how Lynch syndrome non-carriers and carriers translate genetic risk information and advice to decisions about risk managment behaviours in the Australian healthcare system. Methods Participants of the Australasian Colorectal Cancer Family Registry who had undergone predictive genetic testing for Lynch syndrome were interviewed on their risk management behaviours. Transcripts were analysed thematically using a comparative coding analysis. Results Thirty-three people were interviewed. Of the non-carriers (n = 16), 2 reported having apparently unnecessary colonoscopies, and 6 were unsure about what population-based colorectal cancer screening entails. Of the carriers (n = 17), 2 reported they had not had regular colonoscopies, and spoke about their discomfort with the screening process and a lack of faith in the procedure’s ability to reduce their risk of developing colorectal cancer. Of the female carriers (n = 9), 2 could not recall being informed about the associated risk of gynaecological cancers. Conclusion Non-carriers and female carriers of Lynch syndrome could benefit from further clarity and advice about appropriate risk management options. For those carriers who did not adhere to colonoscopy screening, a lack of faith in both genetic test results and screening were evident. It is essential that consistent advice is offered to both carriers and non-carriers of Lynch syndrome.
Collapse
Affiliation(s)
- Emma Steel
- Centre for Health Equity, The University of Melbourne, Melbourne, Australia
| | - Andrew Robbins
- Centre for Health Equity, The University of Melbourne, Melbourne, Australia
| | - Mark Jenkins
- Centre for Epidemiology and Biostatistics, The University of Melbourne, Melbourne, Australia
| | - Louisa Flander
- Centre for Epidemiology and Biostatistics, The University of Melbourne, Melbourne, Australia
| | - Clara Gaff
- Walter and Eliza Hall Institute, Melbourne, Australia
| | - Louise Keogh
- Centre for Health Equity, The University of Melbourne, Melbourne, Australia
| |
Collapse
|
16
|
Health screening behaviors among adults with hereditary hemorrhagic telangiectasia in North America. Genet Med 2016; 19:659-666. [PMID: 27735923 PMCID: PMC5391304 DOI: 10.1038/gim.2016.161] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Accepted: 08/30/2016] [Indexed: 12/24/2022] Open
Abstract
PURPOSE This study aimed to identify factors that influence screening behaviors of adults with hereditary hemorrhagic telangiectasia (HHT). METHODS Participants with a self-reported diagnosis of HHT were recruited from the HHT Foundation International, Inc.; the "HHT Awareness" Facebook group; and six HHT clinics. A cross-sectional mixed methods survey was administered to investigate the relationships among the Health Belief model constructs, the domains of illness representations, and HHT-specific screening behaviors consistent with recommended guidelines. RESULTS A total of 320 participants reported rates of cerebral arteriovenous malformation (AVM) screenings, pulmonary AVM screenings, and HHT annual checkups that were 82.0, 67.1, and 56.5%, respectively. Logistical regression analysis showed that perceived barriers (β = -0.114, P < 0.001), perceived susceptibility (β = 0.117, P < 0.05), treatment control (β = 0.078, P < 0.05), and emotional representations (β = 0.067, P < 0.05) were significant predictors of HHT screening. Open-ended responses revealed perceived barriers to screening, including a lack of health-care providers (HCPs) familiar with and/or knowledgeable about HHT. CONCLUSION Our results reveal suboptimal screening rates among adults with HHT and identify several factors influencing these behaviors. We suggest that there is a need for increased provider education regarding HHT as well as approaches that providers can use to improve screening adherence.Genet Med advance online publication 13 October 2016.
Collapse
|
17
|
Hallowell N, Badger S, Richardson S, Caldas C, Hardwick RH, Fitzgerald RC, Lawton J. An investigation of the factors effecting high-risk individuals' decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC). Fam Cancer 2016; 15:665-76. [PMID: 27256430 PMCID: PMC5935221 DOI: 10.1007/s10689-016-9910-8] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Hereditary diffuse gastric cancer has an early onset and poor prognosis, therefore, individuals who carry a pathogenic (CDH1) mutation in the E-cadherin gene (CDH1) are offered endoscopic surveillance and advised to undergo prophylactic total gastrectomy (PTG) in their early to mid-twenties. Patients not ready or fit to undergo gastrectomy, or in whom the genetic testing result is unknown or ambiguous, are offered surveillance. Little is known about the factors that influence decisions to undergo or decline PTG, making it difficult to provide optimal support for those facing these decisions. Qualitative interviews were carried out with 35 high-risk individuals from the Familial Gastric Cancer Study in the UK. Twenty-seven had previously undergone PTG and eight had been identified as carrying a pathogenic CDH1 mutation but had declined surgery at the time of interview. The interviews explored the experience of decision-making and factors influencing risk-management decisions. The data suggest that decisions to proceed with PTG are influenced by a number of potentially competing factors: objective risk confirmation by genetic testing and/or receiving a positive biopsy; perceived familial cancer burden and associated risk perceptions; perceptions of post-surgical life; an increasing inability to tolerate endoscopic procedures; a concern that surveillance could miss a cancer developing and individual's life stage. These findings have implications for advising this patient group.
Collapse
Affiliation(s)
- Nina Hallowell
- Ethox Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
| | - Shirlene Badger
- PHG Foundation and Institute of Public Health, University of Cambridge, Cambridge, UK
| | | | - Carlos Caldas
- Cambridge University Hospitals Trust, Addenbrookes Hospital, Cambridge, UK
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - Richard H Hardwick
- Cambridge University Hospitals Trust, Addenbrookes Hospital, Cambridge, UK
| | - Rebecca C Fitzgerald
- Cambridge University Hospitals Trust, Addenbrookes Hospital, Cambridge, UK
- MRC Cancer Unit, University of Cambridge, Cambridge, UK
| | - Julia Lawton
- Centre for Population Health Sciences, University of Edinburgh, Cambridge, UK
| |
Collapse
|
18
|
Screening behaviors, health beliefs, and related factors of first-degree relatives of colorectal cancer patients with ongoing treatment in Turkey. Cancer Nurs 2016; 37:E51-60. [PMID: 24476673 DOI: 10.1097/ncc.0000000000000121] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Colorectal cancer (CRC) is one of the most common cancers. Family history is an important risk factor; first-degree relatives (FDRs) are most at risk. Studies are needed to determine the screening behavior of FDRs and factors affecting their health behaviors. OBJECTIVE The purpose of this study was to investigate the screening behaviors, health beliefs, and related factors of FDRs (parent, sibling, or child) of CRC patients undergoing treatment. METHODS A cross-sectional design was used with 400 FDRs of patients undergoing treatment at 2 hospitals in Turkey. Data were collected using the Colorectal Cancer Risk Questionnaire and the Turkish Colorectal Cancer Health Belief Model Scale. RESULTS A slight majority of the participants were male (51.3%), with a mean of age 37.7 years. The rate of having at least 1 colonoscopy in FDRs was 22.2%. First-degree relatives reported high perceived confidence-benefits scores on average (mean, 48.4 ± 5.2) and high perceived barrier scores on average (mean, 15.5 ± 3.8). Health motivation of FDRs was the strongest predictor of their having a colonoscopy (odds ratio, 7.50; 95% confidence interval, 3.40-16.5). CONCLUSIONS First-degree relatives have a low rate of having a colonoscopy but are more likely to have had this procedure if they have strong health motivation. IMPLICATIONS FOR PRACTICE Nurses working with CRC patients must develop strategies to increase FDRs' knowledge of, awareness of, and motivation for CRC screening tests. Risk counseling of FDRs during the treatment period might increase screening rates.
Collapse
|
19
|
Patel SG, Ahnen DJ, Kinney AY, Horick N, Finkelstein DM, Hill DA, Lindor NM, MaCrae F, Lowery JT. Knowledge and Uptake of Genetic Counseling and Colonoscopic Screening Among Individuals at Increased Risk for Lynch Syndrome and their Endoscopists from the Family Health Promotion Project. Am J Gastroenterol 2016; 111:285-93. [PMID: 26856748 PMCID: PMC5193129 DOI: 10.1038/ajg.2015.397] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2015] [Accepted: 11/10/2015] [Indexed: 01/07/2023]
Abstract
OBJECTIVES Individuals whose families meet the Amsterdam II clinical criteria for hereditary non-polyposis colorectal cancer are recommended to be referred for genetic counseling and to have colonoscopic screening every 1-2 years. To assess the uptake and knowledge of guideline-based genetic counseling and colonoscopic screening in unaffected members of families who meet Amsterdam II criteria and their treating endoscopists. METHODS Participants in the Family Health Promotion Project who met the Amsterdam II criteria were surveyed regarding their knowledge of risk-appropriate guidelines for genetic counseling and colonoscopy screening. Endoscopy/pathology reports were obtained from patients screened during the study to determine the follow-up recommendations made by their endoscopists. Survey responses were compared using Fisher's Exact and the χ(2) test. Concordance in participant/provider-reported surveillance interval was assessed using the kappa statistic. RESULTS Of the 165 participants, the majority (98%) agreed that genetics and family history are important predictors of CRC, and 63% had heard of genetic testing for CRC, although only 31% reported being advised to undergo genetic counseling by their doctor, and only 7% had undergone genetic testing. Only 26% of participants reported that they thought they should have colonoscopy every 1-2 years and 30% of endoscopists for these participants recommended 1-2-year follow-up colonoscopy. There was a 65% concordance (weighted kappa 0.42, 95% CI 0.24-0.61) between endoscopist recommendations and participant reports regarding screening intervals. CONCLUSIONS A minority of individuals meeting Amsterdam II criteria in this series have had genetic testing and reported accurate knowledge of risk-appropriate screening, and only a small percentage of their endoscopists provided them with the appropriate screening recommendations. There was moderate concordance between endoscopist recommendations and participant knowledge suggesting that future educational interventions need to target both health-care providers and their patients.
Collapse
Affiliation(s)
- Swati G Patel
- Department of Medicine, Division of Gastroenterology & Hepatology, University of Colorado Anschutz Medical Center, Aurora, Colorado, USA
- Veterans Administration Medical Center, Denver, Colorado, USA
| | - Dennis J Ahnen
- Department of Medicine, Division of Gastroenterology & Hepatology, University of Colorado Anschutz Medical Center, Aurora, Colorado, USA
- Gastroenterology of the Rockies, Boulder, Colorado, USA
| | - Anita Y Kinney
- Department of Internal Medicine, University of New Mexico, Albequerque, New Mexico, USA
| | - Nora Horick
- Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts, USA
| | - Dianne M Finkelstein
- Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts, USA
- Harvard University, Boston, Massachusetts, USA
| | - Deirdre A Hill
- Department of Internal Medicine, Division of Epidemiology, University of New Mexico, Albuquerque, New Mexico, USA
| | | | - Finlay MaCrae
- Department of Colorectal Medicine and Genetics, The Royal Melbourne Hospital Department of Medicine, University of Melbourne, Victoria, Australia
| | - Jan T Lowery
- University of Colorado School of Public Health, Aurora, Colorado, USA
| |
Collapse
|
20
|
Konings ICAW, Sidharta GN, Harinck F, Aalfs CM, Poley JW, Kieffer JM, Kuenen MA, Smets EMA, Wagner A, van Hooft JE, van Rens A, Fockens P, Bruno MJ, Bleiker EMA. Repeated participation in pancreatic cancer surveillance by high-risk individuals imposes low psychological burden. Psychooncology 2015; 25:971-8. [PMID: 26632416 DOI: 10.1002/pon.4047] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Revised: 11/09/2015] [Accepted: 11/13/2015] [Indexed: 12/15/2022]
Abstract
BACKGROUND When assessing the feasibility of surveillance for pancreatic cancer (PC), it is important to address its psychological burden. The aim of this ongoing study is to evaluate the psychological burden of annual pancreatic surveillance for individuals at high risk to develop PC. METHODS This is a multicenter prospective study. High-risk individuals who undergo annual pancreatic surveillance with magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) were invited to complete questionnaires to assess motivations for participating in surveillance, experiences with participation, perceived PC risk, topics of concern, and psychological distress. Questionnaires were sent after intake for participation (T1), after the first MRI and EUS (T2), and after the MRI and EUS 1 (T3), 2 (T4), and 3 years (T5) after first surveillance. RESULTS In total, 140 out of 152 individuals returned one or more of the questionnaires (response 92%); 477 questionnaires were analyzed. The most frequently reported motivation for participating in surveillance was the possible early detection of (a precursor stage of) cancer (95-100%). Only a minority of respondents experienced MRI and EUS as uncomfortable (10% and 11%, respectively), and respondents dreaded their next EUS investigation less as surveillance progressed. Respondents' cancer worries decreased significantly over time, and both their anxiety and depression scores remained stable and low over the 3-year period of follow-up. CONCLUSIONS The psychological burden of pancreatic surveillance is low at all assessments. Therefore, from a psychological point of view, participation of high-risk individuals in an annual pancreatic surveillance program is feasible.Copyright © 2015 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Ingrid C A W Konings
- Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Grace N Sidharta
- Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Femme Harinck
- Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Cora M Aalfs
- Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands
| | - Jan-Werner Poley
- Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Jacobien M Kieffer
- Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Marianne A Kuenen
- Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Ellen M A Smets
- Department of Medical Psychology, Academic Medical Center, Amsterdam, The Netherlands
| | - Anja Wagner
- Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Jeanin E van Hooft
- Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
| | - Anja van Rens
- Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Paul Fockens
- Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
| | - Marco J Bruno
- Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Eveline M A Bleiker
- Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.,Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| |
Collapse
|
21
|
Gimeno-García AZ, Hernández-Álvarez-de-Buylla N, Nicolás-Pérez D, Carrillo M, Hernández G, Quintero E. Colorectal cancer screening in the familial risk population: Is colonoscopy still the strategy of choice? GASTROENTEROLOGIA Y HEPATOLOGIA 2015; 39:352-60. [PMID: 26547615 DOI: 10.1016/j.gastrohep.2015.09.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Revised: 08/22/2015] [Accepted: 09/04/2015] [Indexed: 12/22/2022]
Abstract
First-degree relatives of patients with colorectal cancer (CRC) are at high risk of this disease. For this reason, medical organizations and clinical guidelines recommend more intensive screening and surveillance for such first-degree relatives than for the average-risk population. Colonoscopy has been the cornerstone of CRC screening in this setting. Although colonoscopy is the most sensitive technique for the detection of neoplastic lesions (especially non-advanced adenomas), its role is less clear for CRC. In addition, screening colonoscopy has several limitations that may affect the success of a screening campaign, such as poor participant acceptance, the need for skilled endoscopists, participant access to screening colonoscopy, overburdened endoscopy units, potential complications, and procedure-related costs. In addition, recent evidence has cast doubt on the advantage of colonoscopy over other strategies for the detection of advanced neoplastic lesions. Despite being less sensitive in general, other screening methods frequently recommended in the average-risk population may be more acceptable and thus help increase CRC screening uptake. This review discusses recent evidence on the risk of CRC in first-degree relatives, the advantages and disadvantages of each screening technique, participation rates depending on the technique, patient preferences, and barriers to screening.
Collapse
Affiliation(s)
- Antonio Z Gimeno-García
- Servicio de Gastroenterología, Hospital Universitario de Canarias, Instituto Universitario de Tecnologías Biomédicas (ITB) & Centro de Investigación Biomédica de Canarias (CIBICAN), Departamento de Medicina Interna, Universidad de La Laguna, C.P. 38320 Tenerife, Spain.
| | - Noemi Hernández-Álvarez-de-Buylla
- Servicio de Gastroenterología, Hospital Universitario de Canarias, Instituto Universitario de Tecnologías Biomédicas (ITB) & Centro de Investigación Biomédica de Canarias (CIBICAN), Departamento de Medicina Interna, Universidad de La Laguna, C.P. 38320 Tenerife, Spain
| | - David Nicolás-Pérez
- Servicio de Gastroenterología, Hospital Universitario de Canarias, Instituto Universitario de Tecnologías Biomédicas (ITB) & Centro de Investigación Biomédica de Canarias (CIBICAN), Departamento de Medicina Interna, Universidad de La Laguna, C.P. 38320 Tenerife, Spain
| | - Marta Carrillo
- Servicio de Gastroenterología, Hospital Universitario de Canarias, Instituto Universitario de Tecnologías Biomédicas (ITB) & Centro de Investigación Biomédica de Canarias (CIBICAN), Departamento de Medicina Interna, Universidad de La Laguna, C.P. 38320 Tenerife, Spain
| | - Goretti Hernández
- Servicio de Gastroenterología, Hospital Universitario de Canarias, Instituto Universitario de Tecnologías Biomédicas (ITB) & Centro de Investigación Biomédica de Canarias (CIBICAN), Departamento de Medicina Interna, Universidad de La Laguna, C.P. 38320 Tenerife, Spain
| | - Enrique Quintero
- Servicio de Gastroenterología, Hospital Universitario de Canarias, Instituto Universitario de Tecnologías Biomédicas (ITB) & Centro de Investigación Biomédica de Canarias (CIBICAN), Departamento de Medicina Interna, Universidad de La Laguna, C.P. 38320 Tenerife, Spain
| |
Collapse
|
22
|
Hennink SD, van der Meulen-de Jong AE, Wolterbeek R, Crobach ASLP, Becx MCJM, Crobach WFSJ, van Haastert M, Ten Hove WR, Kleibeuker JH, Meijssen MAC, Nagengast FM, Rijk MCM, Salemans JMJI, Stronkhorst A, Tuynman HARE, Vecht J, Verhulst ML, de Vos Tot Nederveen Cappel WH, Walinga H, Weinhardt OK, Westerveld D, Witte AMC, Wolters HJ, Cats A, Veenendaal RA, Morreau H, Vasen HFA. Randomized Comparison of Surveillance Intervals in Familial Colorectal Cancer. J Clin Oncol 2015; 33:4188-93. [PMID: 26527788 DOI: 10.1200/jco.2015.62.2035] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
PURPOSE Colonoscopic surveillance is recommended for individuals with familial colorectal cancer (CRC). However, the appropriate screening interval has not yet been determined. The aim of this randomized trial was to compare a 3-year with a 6-year screening interval. PATIENTS AND METHODS Individuals between ages 45 and 65 years with one first-degree relative with CRC age < 50 years or two first-degree relatives with CRC were selected. Patients with zero to two adenomas at baseline were randomly assigned to one of two groups: group A (colonoscopy at 6 years) or group B (colonoscopy at 3 and 6 years). The primary outcome measure was advanced adenomatous polyps (AAPs). Risk factors studied included sex, age, type of family history, and baseline endoscopic findings. RESULTS A total of 528 patients were randomly assigned (group A, n = 262; group B, n = 266). Intention-to-treat analysis showed no significant difference in the proportion of patients with AAPs at the first follow-up examination at 6 years in group A (6.9%) versus 3 years in group B (3.5%). Also, the proportion of patients with AAPs at the final follow-up examination at 6 years in group A (6.9%) versus 6 years in group B (3.4%) was not significantly different. Only AAPs at baseline was a significant predictor for the presence of AAPs at first follow-up. After correction for the difference in AAPs at baseline, differences between the groups in the rate of AAPs at first follow-up and at the final examination were statistically significant. CONCLUSION In view of the relatively low rate of AAPs at 6 years and the absence of CRC in group A, we consider a 6-year surveillance interval appropriate. A surveillance interval of 3 years might be considered in patients with AAPs and patients with ≥ three adenomas.
Collapse
Affiliation(s)
- Simone D Hennink
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Andrea E van der Meulen-de Jong
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Ron Wolterbeek
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - A Stijn L P Crobach
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Marco C J M Becx
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Wiet F S J Crobach
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Michiel van Haastert
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - W Rogier Ten Hove
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Jan H Kleibeuker
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Maarten A C Meijssen
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Fokko M Nagengast
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Marno C M Rijk
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Jan M J I Salemans
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Arnold Stronkhorst
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Hans A R E Tuynman
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Juda Vecht
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Marie-Louise Verhulst
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Wouter H de Vos Tot Nederveen Cappel
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Herman Walinga
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Olaf K Weinhardt
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Dik Westerveld
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Anne M C Witte
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Hugo J Wolters
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Annemieke Cats
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Roeland A Veenendaal
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Hans Morreau
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands
| | - Hans F A Vasen
- Simone D. Hennink, Andrea E. van der Meulen-de Jong, Ron Wolterbeek, A. Stijn L.P. Crobach, Roeland A. Veenendaal, Hans Morreau, and Hans F.A. Vasen, Leiden University Medical Center; Wiet F.S.J. Crobach, W. Rogier ten Hove, and Anne M.C. Witte, Diaconessenhuis, Leiden; Marco C.J.M. Becx, St Antonius Hospital, Nieuwegein; Michiel van Haastert and Hugo J. Wolters, Martini Hospital; Jan H. Kleibeuker, University Medical Center Groningen, Groningen; Maarten A.C. Meijssen, Juda Vecht, Wouter H. de Vos tot Nederveen Cappel, and Dik Westerveld, Isala Clinics, Zwolle; Fokko M. Nagengast, Radboud University Medical Center, Nijmegen; Marno C.M. Rijk, Amphia Hospital, Breda; Jan M.J.I. Salemans and Marie-Louise Verhulst, Máxima Medical Center; Arnold Stronkhorst, Catharina Hospital, Eindhoven; Hans A.R.E. Tuynman, Medical Center Alkmaar, Alkmaar; Herman Walinga, Reinier de Graaf Gasthuis, Delft; Olaf K. Weinhardt, Scheper Hospital, Emmen; and Annemieke Cats, National Cancer Institute, Amsterdam, the Netherlands.
| |
Collapse
|
23
|
Frey MK, Pauk SJ, Caputo TA, Moss HA, Sapra KJ, Gerber D, Stewart JD. Availability and scope of integrated screening for patients with Lynch syndrome. Int J Gynaecol Obstet 2015; 131:142-6. [PMID: 26365573 DOI: 10.1016/j.ijgo.2015.05.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Revised: 05/21/2015] [Accepted: 07/29/2015] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To assess the availability and capacity of US-based integrated centers for the management of Lynch syndrome. METHODS A cross-sectional survey of practice patterns in the care of patients with Lynch syndrome was conducted at 33 National Cancer Institute-designated cancer centers in the USA from March 1 to June 1, 2013. Each cancer center was contacted by telephone and the caller used a uniform scripted greeting and survey format. RESULTS All centers routinely recommended colonoscopy. Other recommended screening modalities were hysterectomy and bilateral salpingo-oophorectomy (29/33; 88%), endoscopy (27/33; 82%), urinalysis (23/33; 70%), endometrial sampling (21/33; 64%), dermatologic examination (19/32; 59%), pelvic ultrasonography (18/33; 55%), serum CA125 level (14/33; 42%), urine cytology (14/33; 42%), computed tomography (1/33; 3%), and magnetic resonance imaging (1/33; 3%). Each center had a multidisciplinary team but the composition varied. A designated team leader was present at 21 centers (64%). Having a team leader was associated with an increased likelihood of recommending endoscopy (P=0.04) and dermatologic surveillance (P=0.01). Only 23 centers (70%) had a system in place for communicating follow-up with patients. CONCLUSION The lack of consensus in practice patterns recorded among participating centers probably reflected the limited existing evidence on the usefulness of most screening modalities.
Collapse
Affiliation(s)
- Melissa K Frey
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, New York University Langone Medical Center, New York, NY, USA.
| | - Sara J Pauk
- Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, USA
| | - Thomas A Caputo
- Department of Epidemiology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - Haley A Moss
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, New York University Langone Medical Center, New York, NY, USA
| | - Katherine J Sapra
- Department of Epidemiology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - Deanna Gerber
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA
| | - Joshua D Stewart
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA
| |
Collapse
|
24
|
Bastani R, Glenn BA, Maxwell AE, Ganz PA, Mojica CM, Alber S, Crespi CM, Chang LC. Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives. Cancer 2015; 121:2951-9. [PMID: 25946376 PMCID: PMC4545725 DOI: 10.1002/cncr.29403] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2014] [Revised: 03/06/2015] [Accepted: 03/12/2015] [Indexed: 12/18/2022]
Abstract
BACKGROUND Ethnic minorities, especially African Americans and Latinos, bear a disproportionate burden of colorectal cancer (CRC), as reflected in incidence, cancer stage, and mortality statistics. In all ethnic groups, first-degree relatives (FDRs) of CRC cases are at an elevated disease risk. However, underuse of CRC screening persists and is particularly evident among minority groups. The current study tested a stepped intervention to increase CRC screening among an ethnically diverse sample of FDRs of CRC cases. METHODS A statewide cancer registry was used to recruit CRC cases and through them their FDRs. Relatives who were not current on CRC screening were randomized to intervention or usual-care control arms. The stepped intervention consisted of ethnically targeted and individually tailored print materials followed by telephone counseling for those unscreened at 6 months. RESULTS The study sample of 1280 individuals consisted of 403 Latino, 284 African American, 242 Asian, and 351 white FDRs. Statistically significant effects were observed for the cumulative print plus telephone intervention at 12 months (26% in the intervention vs 18% in the control group) and the print intervention alone at 6 months (15% in the intervention vs 10% in the control group). The effect of the print intervention alone versus the cumulative interventions was not statistically significantly different. Stratified analyses indicated that the intervention was effective among white, Latino, and Asian individuals, but not among African-Americans. CONCLUSIONS Overall, the intervention was effective in increasing screening rates. Oversampling racial/ethnic minorities allowed for the examination of effects within subgroups, revealing no effect among African American individuals. This finding illustrates the importance of including sufficient numbers of participants from diverse ethnic subgroups in intervention research to enable such stratified analyses.
Collapse
Affiliation(s)
- Roshan Bastani
- Fielding School of Public Health, Jonsson Comprehensive Cancer Center, UCLA Kaiser Permanente Center for Health Equity, University of California, Los Angeles, CA
| | - Beth A. Glenn
- Fielding School of Public Health, Jonsson Comprehensive Cancer Center, UCLA Kaiser Permanente Center for Health Equity, University of California, Los Angeles, CA
| | - Annette E. Maxwell
- Fielding School of Public Health, Jonsson Comprehensive Cancer Center, UCLA Kaiser Permanente Center for Health Equity, University of California, Los Angeles, CA
| | - Patricia A. Ganz
- Fielding School of Public Health, Jonsson Comprehensive Cancer Center, UCLA Kaiser Permanente Center for Health Equity, University of California, Los Angeles, CA
| | - Cynthia M. Mojica
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - Susan Alber
- Department of Statistics, Volgenau School of Engineering, George Mason University, Fairfax, VA
| | - Catherine M. Crespi
- Fielding School of Public Health, Jonsson Comprehensive Cancer Center, UCLA Kaiser Permanente Center for Health Equity, University of California, Los Angeles, CA
| | - L. Cindy Chang
- Fielding School of Public Health, Jonsson Comprehensive Cancer Center, UCLA Kaiser Permanente Center for Health Equity, University of California, Los Angeles, CA
| |
Collapse
|
25
|
Atkinson TM, Salz T, Touza KK, Li Y, Hay JL. Does colorectal cancer risk perception predict screening behavior? A systematic review and meta-analysis. J Behav Med 2015; 38:837-50. [PMID: 26280755 DOI: 10.1007/s10865-015-9668-8] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Accepted: 08/07/2015] [Indexed: 01/22/2023]
Abstract
Although health behavior theories postulate that risk perception should motivate colorectal cancer (CRC) screening, this relationship is unclear. This meta-analysis aims to examine the relationship between CRC risk perception and screening behavior, while considering potential moderators and study quality. A search of six databases yielded 58 studies (63 effect sizes) that quantitatively assessed the relationship between CRC risk perception and screening behavior. Most included effect sizes (75 %) reported a positive association between CRC risk perception and screening behavior. A random effects meta-analysis yielded an overall effect size of z = 0.13 (95 % CI 0.10-0.16), which was heterogeneous (I (2) = 99 %, τ(2) = 0.01). Effect sizes from high-quality studies were significantly lower than those from lower quality studies (z = 0.02 vs. 0.16). We found a small, positive relationship between CRC risk perception and reported screening behavior, with important identified heterogeneity across moderators. Future studies should focus on high quality study design.
Collapse
Affiliation(s)
- Thomas M Atkinson
- Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave., 7th Floor, New York, NY, 10022, USA.
| | - Talya Salz
- Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave., 7th Floor, New York, NY, 10022, USA.
| | - Kaitlin K Touza
- Indiana University-Purdue University Indianapolis, Indianapolis, IN, USA.
| | - Yuelin Li
- Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave., 7th Floor, New York, NY, 10022, USA.
| | - Jennifer L Hay
- Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave., 7th Floor, New York, NY, 10022, USA.
| |
Collapse
|
26
|
Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X, Yu L, Wang L, Wang J, Wu Y, Chen Z, Zhu H. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer 2015; 136:152-61. [PMID: 23456911 DOI: 10.1002/ijc.28136] [Citation(s) in RCA: 119] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2012] [Accepted: 02/11/2013] [Indexed: 12/19/2022]
Abstract
Colonoscopy remains the standard screening method for detecting colorectal cancer (CRC) at an early stage. However, many people avoid having a colonoscopy because of the fear for its potential complications. Our study aimed to identify plasma microRNAs for preliminarily screening CRC in general population, so that some unnecessary colonoscopies can be avoided. We investigated plasma microRNA expression in three independent cohorts including the discovery (n = 80), training (n = 112), and validation (n = 49) phases recruited at two medical centers. Microarrays were used for screening 723 microRNAs in 80 plasma samples to identify candidate microRNAs. Quantitative reverse-transcriptase PCR was performed on the 161 training and validation plasma samples to evaluate the candidate microRNAs discovered from microarrays. A logistic regression model was constructed based on the training cohort and then verified by using the validation dataset. Area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic accuracy. We identified a panel of miR-409-3p, miR-7, and miR-93 that yielded high diagnostic accuracy in discriminating CRC from healthy group (AUC: 0.866 and 0.897 for training and validation dataset, respectively). Moreover, the diagnostic performance of the microRNA panel persisted in nonmetastasis CRC stages (Dukes' A-B, AUC: 0.809 and 0.892 for training and validation dataset, respectively) and in metastasis CRC stages (Dukes' C-D, AUC: 0.917 and 0.865 for training and validation dataset, respectively). In conclusion, our study reveals a plasma microRNA panel that has potential clinical value in early CRC detection and would play a critical role on preliminarily screening CRC in general population.
Collapse
Affiliation(s)
- Shuyang Wang
- Department of Pathology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Bikhchandani J, Lynch HT. Commentary on 'Colonoscopy screening compliance and outcomes in patients with Lynch syndrome'. Colorectal Dis 2015; 17:46-9. [PMID: 25536883 DOI: 10.1111/codi.12841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Jai Bikhchandani
- Creighton University, 2500 California Plaza, Omaha, Nebraska, 68102, USA
| | | |
Collapse
|
28
|
Newton K, Green K, Lalloo F, Evans DG, Hill J. Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. Colorectal Dis 2015; 17:38-46. [PMID: 25213040 DOI: 10.1111/codi.12778] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2014] [Accepted: 07/15/2014] [Indexed: 12/14/2022]
Abstract
AIM Colonic surveillance reduces the lifetime risk of colorectal cancer in patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer) from 60 to 80% to 10% and confers a 7-year survival advantage. The British Society of Gastroenterologists recommends colonoscopy at least every 2 years from the age of 25. Currently in the UK, genetic diagnosis is made by a regional genetics service, and screening recommendations are made to the referring clinician. The aim of this study was to investigate compliance with and the effectiveness of large bowel surveillance in Lynch syndrome. METHOD A retrospective longitudinal study of Lynch syndrome mutation carriers on the Regional Familial Colorectal Cancer Registry under and not under screening was conducted. To investigate screening compliance, patients were included if they were alive at the start of the study. Data were gathered on timeliness, quality and outcome of screening. To examine the effectiveness of screening, the cumulative incidence of colorectal cancer was estimated using Kaplan-Meier curves and the screened population compared with patients not being screened. RESULTS A total of 227 Lynch syndrome mutation carriers were under screening at 26 hospitals. We assessed 439 colonoscopies for timeliness, of which 68% were compliant (interval < 27 months). Compliance on the 1 November 2011 was 87%. The cumulative incidence of colorectal cancer to the age of 70 was 25% (95% CI 17-32%) in the surveillance population and 81% (95% CI 78-84%) in 689 mutation-positive patients not being screened (P < 0.0001). CONCLUSION Overall, 68% of colonoscopies were on time. The incidence of colorectal cancer was greatly reduced by screening but remained significant. Patients with Lynch syndrome need proactive surveillance management.
Collapse
Affiliation(s)
- K Newton
- Department of General Surgery, Manchester Royal Infirmary, Manchester, UK
| | | | | | | | | |
Collapse
|
29
|
Adakan Y, Taskoparan M, Cekin AH, Duman A, Harmandar F, Taskin V, Yilmaz U, Yesil B. Implementation of screening colonoscopy amongst first- degree relatives of patients with colorectal cancer in Turkey: a cross-sectional questionnaire based survey. Asian Pac J Cancer Prev 2014; 15:5523-8. [PMID: 25081658 DOI: 10.7314/apjcp.2014.15.14.5523] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE To evaluate the implementation of screening colonoscopy amongst first-degree relatives (FDRs) of patients with colorectal cancer (CRC) in Turkey. MATERIALS AND METHODS A total of 400 first-degree relatives (mean(SD)age: 42.5(12.7) years, 55.5% were male) of 136 CRC patients were included in this cross-sectional questionnaire based survey. Data on demographic characteristics, relationship to patient and family history for malignancy other than the index case were evaluated in the FDRs of patients as were the data on knowledge about and characteristics related to the implementation of screening colonoscopy using a standardized questionnaire form. RESULTS The mean(SD) age at diagnosis of CRC in the index patients was 60.0(14.0) years, while mean(SD) age of first degree relatives was 42.5(12.7) years. Overall 36.3% of relatives were determined to have knowledge about colonoscopy. Physicians (66.9%) were the major source of information. Screening colonoscopy was recommended to 19.5% (n=78) of patient relatives, while 48.7% (n=38) of individuals participated in colonoscopy procedures, mostly (57.9%) one year after the index diagnosis. Screening colonoscopy revealed normal findings in 25 of 38 (65.8%) cases, while precancerous lesions were detected in 26.3% of screened individuals. In 19.0% of FDRs of patients, there was a detected risk for Lynch syndrome related cancer. CONCLUSIONS In conclusion, our findings revealed that less than 20% of FDRs of patients had received a screening colonoscopy recommendation; only 48.7% participated in the procedure with detection of precancerous lesions in 26.3%. Rise of awareness about screening colonoscopy amongst patients with CRC and first degree relatives of patients and motivation of physicians for targeted screening would improve the participation rate in screening colonoscopy by FDRs of patients with CRC in Turkey.
Collapse
Affiliation(s)
- Yesim Adakan
- Department of Internal Medicine, Antalya Training and Research Hospital, Antalya, Turkey E-mail :
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Boonyasiriwat W, Hung M, Hon SD, Tang P, Pappas LM, Burt RW, Schwartz MD, Stroup AM, Kinney AY. Intention to undergo colonoscopy screening among relatives of colorectal cancer cases: a theory-based model. Ann Behav Med 2014; 47:280-91. [PMID: 24307472 DOI: 10.1007/s12160-013-9562-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND It is recommended that persons having familial risk of colorectal cancer begin regular colonoscopy screening at an earlier age than those in the general population. However, many individuals at increased risk do not adhere to these screening recommendations. PURPOSE The goal of this study was to examine cognitive, affective, social, and behavioral motivators of colonoscopy intention among individuals at increased risk of familial colorectal cancer. METHODS Relatives of colorectal cancer cases (N = 481) eligible for colonoscopy screening completed a survey assessing constructs from several theoretical frameworks including fear appeal theories. RESULTS Structural equation modeling indicated that perceived colorectal cancer risk, past colonoscopy, fear of colorectal cancer, support from family and friends, and health-care provider recommendation were determinants of colonoscopy intention. CONCLUSIONS Future interventions to promote colonoscopy in this increased risk population should target the factors we identified as motivators. (ClinicalTrials.gov number NCT01274143).
Collapse
|
31
|
Lowery JT, Horick N, Kinney AY, Finkelstein DM, Garrett K, Haile RW, Lindor NM, Newcomb PA, Sandler RS, Burke C, Hill DA, Ahnen DJ. A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network. Cancer Epidemiol Biomarkers Prev 2014; 23:601-10. [PMID: 24501379 PMCID: PMC3976708 DOI: 10.1158/1055-9965.epi-13-1085] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Individuals with a strong family history of colorectal cancer have significant risk for colorectal cancer, although adherence to colonoscopy screening in these groups remains low. This study assessed whether a tailored telephone counseling intervention can increase adherence to colonoscopy in members of high-risk families in a randomized, controlled trial. METHODS Eligible participants were recruited from two national cancer registries if they had a first-degree relative with colorectal cancer under age 60 or multiple affected family members, which included families that met the Amsterdam criteria for hereditary non-polyposis colon cancer (HNPCC), and if they were due for colonoscopy within 24 months. Participants were randomized to receive a tailored telephone intervention grounded in behavioral theory or a mailed packet with general information about screening. Colonoscopy status was assessed through follow-up surveys and endoscopy reports. Cox proportional hazards models were used to assess intervention effect. RESULTS Of the 632 participants (ages 25-80), 60% were female, the majority were White, non-Hispanic, educated, and had health insurance. Colonoscopy adherence increased 11 percentage points in the tailored telephone intervention group, compared with no significant change in the mailed group. The telephone intervention was associated with a 32% increase in screening adherence compared with the mailed intervention (HR, 1.32; P = 0.01). CONCLUSIONS A tailored telephone intervention can effectively increase colonoscopy adherence in high-risk persons. This intervention has the potential for broad dissemination to healthcare organizations or other high-risk populations. IMPACT Increasing adherence to colonoscopy among persons with increased colorectal cancer risk could effectively reduce incidence and mortality from this disease.
Collapse
Affiliation(s)
- Jan T Lowery
- Authors' Affiliations: Colorado School of Public Health, University of Colorado; University of Colorado Cancer Center, Division of Cancer Prevention and Control, Aurora; Department of Medicine, Department of Veterans Affairs Eastern Colorado Health Care System and University of Colorado School of Medicine, Denver, Colorado; Massachusetts General Hospital Biostatistics Center; Harvard University, Boston, Massachusetts; Division of Epidemiology, Biostatistics, and Prevention, Department of Internal Medicine; Cancer Center, University of New Mexico, Albuquerque, New Mexico; Stanford University, Population Sciences, Stanford, California; Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona; Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of North Carolina, Chapel Hill, North Carolina; and Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
In the care of patients with Lynch Syndrome (LS), a range of psychosocial issues are encountered, which significantly affect patient outcomes. A brief historical background of 'psycho-onco-genetics' (the domain where psychology, oncology and genetics meet) in relation to LS is presented, followed by an overview of important psychosocial issues identified in the past 20 years. The identification of mismatch repair genes in 1993-1994 made possible genetic counseling and testing for patients who had cancer and for potentially high-risk relatives without cancer. At that time, concerns were raised about the potentially negative psychosocial impact of predictive genetic testing. Since 1993, a large number of studies have been conducted to investigate the possible psychosocial benefits and limitations of such testing. This article presents an overview of: the uptake of and motivations for genetic testing, its psychosocial impact (e.g. psychological adaptation, impact on risk perception and self-concept, and concerns about, and experiences of, genetic discrimination), psychological screening instruments, adherence to and decision-making about preventive strategies, family communication, lifestyle changes, reproductive technology utilization, and professional psychosocial support needs of members of families with LS. Finally, challenges for the future are discussed, including population screening and genomic testing.
Collapse
|
33
|
Rothenmund H, Singh H, Candas B, Chodirker BN, Serfas K, Aronson M, Holter S, Volenik A, Green J, Dicks E, Woods MO, Gilchrist D, Gryfe R, Cohen Z, Foulkes WD. Hereditary colorectal cancer registries in Canada: report from the Colorectal Cancer Association of Canada consensus meeting; Montreal, Quebec; October 28, 2011. ACTA ACUST UNITED AC 2013; 20:273-8. [PMID: 24155632 DOI: 10.3747/co.20.1566] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
At a consensus meeting held in Montreal, October 28, 2011, a multidisciplinary group of Canadian experts in the fields of genetics, gastroenterology, surgery, oncology, pathology, and health care services participated in presentation and discussion sessions for the purpose of developing consensus statements pertaining to the development and maintenance of hereditary colorectal cancer registries in Canada. Five statements were approved by all participants.
Collapse
Affiliation(s)
- H Rothenmund
- Hereditary Colorectal Cancer Registry, Cancer Prevention Centre, Jewish General Hospital, Montreal, QC
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Al-Dubai SAR, Ganasegeran K, Alabsi AM, Shah SA, Razali FMM, Arokiasamy JT. Exploration of risk taking behaviors and perceived susceptibility of colorectal cancer among Malaysian adults: a community based cross-sectional study. BMC Public Health 2013; 13:930. [PMID: 24093502 PMCID: PMC3851727 DOI: 10.1186/1471-2458-13-930] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2013] [Accepted: 10/02/2013] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Perceived susceptibility to an illness has been shown to affect Health-risk behavior. The objective of the present study was to determine the risk taking behaviors and the demographic predictors of perceived susceptibility to colorectal cancer in a population-based sample. METHODS A cross-sectional study was carried out among 305 Malaysian adults in six major districts, selected from urban, semi-urban, and rural settings in one state in Malaysia. A self-administered questionnaire was used in this study. It was comprised of socio-demographics, risk-taking behaviors, and validated domains of the Health Belief Model (HBM). RESULTS The mean (± SD) age of the respondents was 34.5 (± 9.6) and the majority (59.0%) of them were 30 years or older. Almost 20.7% of the respondents felt they were susceptible to colorectal cancer. Self-reported perceived susceptibility mirrored unsatisfactory screening behaviors owing to the lack of doctors' recommendation, ignorance of screening modalities, procrastination, and the perception that screening was unnecessary. Factors significantly associated with perceived susceptibility to colorectal cancer were gender (OR = 1.8, 95% CI 1.0-3.3), age (OR = 2. 2, 95% CI 1.2-4.0), ethnicity (OR = 0. 3, 95% CI 0.2-0.6), family history of colorectal cancer (OR = 3. 2, 95% CI 1.4-7.4) and alcohol intake (OR = 3.9, 95% CI 2.1-7.5). CONCLUSION The present study revealed that screening behavior among respondents was unsatisfactory. Hence, awareness of the importance of screening to prevent colorectal cancers is imperative.
Collapse
Affiliation(s)
- Sami AR Al-Dubai
- Department of Community Medicine, International Medical University (IMU), No. 126, Jln Jalil Perkasa 19, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
| | - Kurubaran Ganasegeran
- International Medical School, Management and Science University (MSU), University Drive, Off Persiaran Olahraga, Section 13, 40100 Shah Alam, Selangor, Malaysia
| | - Aied M Alabsi
- Oral Cancer Research And Coordinating Center, Faculty of Dentistry, University of Malaya (UM), Kuala Lumpur 50603 Malaysia
| | - Shamsul A Shah
- Department of Community Health, UKM Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, 56000 Kuala Lumpur, Malaysia
| | - Farid MM Razali
- Perdana University Graduate School of Medicine, Perdana University, Maeps Building, Mardi Complex, 43400 Serdang, SelangorMalaysia
| | - John T Arokiasamy
- Department of Community Medicine, International Medical University (IMU), No. 126, Jln Jalil Perkasa 19, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
| |
Collapse
|
35
|
Schneider KI, Schmidtke J. Patient compliance based on genetic medicine: a literature review. J Community Genet 2013; 5:31-48. [PMID: 23934761 DOI: 10.1007/s12687-013-0160-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2012] [Accepted: 07/02/2013] [Indexed: 12/19/2022] Open
Abstract
For this literature review, medical literature data bases were searched for studies on patient compliance after genetic risk assessment. The review focused on conditions where secondary or tertiary preventive options exist, namely cancer syndromes (BRCA-related cancer, HNPCC/colon cancer), hemochromatosis, thrombophilia, smoking cessation, and obesity. As a counterpart, patient compliance was assessed regarding medication adherence and medical advice in some of the most epidemiologically important conditions (including high blood pressure, metabolic syndrome, and coronary heart disease) after receiving medical advice based on nongenetic risk information or a combination of genetic and nongenetic risk information. In the majority of studies based on genetic risk assessments, patients were confronted with predictive rather than diagnostic genetic profiles. Most of the studies started from a knowledge base around 10 years ago when DNA testing was at an early stage, limited in scope and specificity, and costly. The major result is that overall compliance of patients after receiving a high-risk estimate from genetic testing for a given condition is high. However, significant behavior change does not take place just because the analyte is "genetic." Many more factors play a role in the complex process of behavioral tuning. Without adequate counseling and guidance, patients may interpret risk estimates of predictive genetic testing with an increase in fear and anxiety.
Collapse
Affiliation(s)
- Kai Insa Schneider
- Institute of Human Genetics, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany
| | | |
Collapse
|
36
|
Experimental assessment of a novel robotically-driven endoscopic capsule compared to traditional colonoscopy. Dig Liver Dis 2013; 45:657-62. [PMID: 23453360 DOI: 10.1016/j.dld.2013.01.025] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2012] [Revised: 12/23/2012] [Accepted: 01/22/2013] [Indexed: 12/11/2022]
Abstract
BACKGROUND Despite colonoscopy represents the conventional diagnostic tool for colorectal pathology, its undeniable discomfort reduces compliance to screening programmes. AIMS To evaluate feasibility and accuracy of a novel robotically-driven magnetic capsule for colonoscopy as compared to the traditional technique. METHODS Eleven experts and eleven trainees performed complete colonoscopy by robotic magnetic capsule and by conventional colonoscope in a phantom ex vivo model (artificially clean swine bowel). Feasibility, overall accuracy to detect installed pins, procedure elapsed time and intuitiveness were measured for both techniques in both operator groups. RESULTS Complete colonoscopy was feasible in all cases with both techniques. Overall 544/672 pins (80.9%) were detected by experimental capsule procedure, while 591/689 pins (85.8%) were detected within conventional colonoscopy procedure (P=ns), thus establishing non-inferiority. With the experimental capsule procedure, experts detected 74.2% of pins vs. 87.6% detected by trainees (P<0.0001). Overall time to complete colon inspection by robotic capsule was significantly higher than by conventional colonoscopy (556±188s vs. 194±158s, respectively; P=0.0001). CONCLUSION With the limitations represented by an ex vivo setting (artificially clean swine bowel and the absence of peristalsis), colonoscopy by this novel robotically-driven capsule resulted feasible and showed adequate accuracy compared to conventional colonoscopy.
Collapse
|
37
|
Baucom RB, Wise PE. Endoscopic and surgical management of hereditary nonpolyposis colorectal cancer. Clin Colon Rectal Surg 2013; 25:90-6. [PMID: 23730223 DOI: 10.1055/s-0032-1313779] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome is a disease characterized by autosomal dominant clustering of colorectal cancer (CRC) as well as other cancers. It is critical for clinicians and surgeons caring for patients with HNPCC to be familiar with their management related to CRC. Based on retrospective studies, screening colonoscopy is recommended every 1 to 2 years beginning at age 20 to 25, or 10 years younger than the earliest CRC in the family (whichever is earlier). HNPCC patients with colon cancer should be considered for total abdominal colectomy rather than a more limited segmental colon resection due to the increased risk of metachronous neoplasia associated with the condition. Rectal cancer in HNPCC has not been well studied, but discussions with the patient regarding surgical management should weigh the risks of metachronous CRC with the morbidity and quality of life issues associated with proctocolectomy. Regardless of the procedure, a patient with HNPCC requires close postoperative endoscopic surveillance of any remaining at-risk mucosa. In terms of chemoprevention, aspirin has been shown to be effective in preventing colorectal neoplasia in prospective trials and should be considered in patients who do not have a contraindication to the drug. Trials for other chemopreventative agents in HNPCC are ongoing. As more is learned about particular genotype-phenotype correlations with Lynch syndrome, this will likely affect surgical decision making. Despite all of these efforts in the management of patients with HNPCC or Lynch syndrome, incident CRCs still occur, thus reinforcing the need for further studies to better understand the optimal management of these patients.
Collapse
Affiliation(s)
- Rebeccah B Baucom
- Section of Surgical Sciences, Vanderbilt University Medical Center, Nashville, Tennessee
| | | |
Collapse
|
38
|
Burton AM, Hovick SR, Peterson SK. Health behaviors in patients and families with hereditary colorectal cancer. Clin Colon Rectal Surg 2013; 25:111-7. [PMID: 23730226 DOI: 10.1055/s-0032-1313782] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
It is estimated that 5 to 10% of all colorectal cancer (CRC) cases are attributed to a hereditary cause. The primary hereditary cancer syndromes that confer an increased risk for colorectal cancers are Lynch syndrome/hereditary nonpolyposis colorectal cancer (HNPCC) and familial adenomatous polyposis (FAP). Through genetic testing, health care providers can identify patients and families who carry gene mutations and subsequently are at a substantially greater risk for developing colorectal cancer than the general population. Genetic testing provides risk information not only about an individual patient, but also his or her biological relatives. A variety of risk-reduction behaviors (including screening, surgery, and health and lifestyle behaviors) have been examined in Lynch syndrome and FAP populations. The research indicates that screening behaviors are less than optimal, although the rates vary from study to study. Prophylactic colectomy is the primary course of treatment for individuals who test positive for a FAP mutation, but the results are inconclusive for cancer-unaffected Lynch syndrome mutation carriers. Although research suggests that the adoption of healthy lifestyles and behaviors (e.g., diet, physical activity, weight control, smoking cessation, limited alcohol consumption) could have a favorable impact on colon cancer burden, there is minimal data on how these behaviors may moderate cancer risk among those at risk of hereditary colon cancer. To date, we know very little about the actual health and lifestyle behaviors of those at risk of hereditary colon cancer. Genetic testing and counseling at risk individuals may resolve uncertainty about their personal and familial cancer risk and provide information to guide and personalize decisions about their future health care.
Collapse
Affiliation(s)
- Allison M Burton
- Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | | |
Collapse
|
39
|
Kilpivaara O, Aaltonen LA. Diagnostic cancer genome sequencing and the contribution of germline variants. Science 2013; 339:1559-62. [PMID: 23539595 DOI: 10.1126/science.1233899] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Whole-genome sequencing (WGS) is revolutionizing medical research and has the potential to serve as a powerful and cost-effective diagnostic tool in the management of cancer. We review the progress to date in the use of WGS to reveal how germline variants and mutations may be associated with cancer. We use colorectal cancer as an example of how the current level of knowledge can be translated into predictions of predisposition. We also address challenges in the clinical implementation of the variants in germline DNA identified through cancer genome sequencing. We call for the international development of standards to facilitate the clinical use of germline information arising from diagnostic cancer genome sequencing.
Collapse
Affiliation(s)
- O Kilpivaara
- Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
| | | |
Collapse
|
40
|
Dekker N, Hermens RPMG, Nagengast FM, van Zelst-Stams WAG, Hoogerbrugge N. Familial colorectal cancer risk assessment needs improvement for more effective cancer prevention in relatives. Colorectal Dis 2013; 15:e175-85; discussion p.e185. [PMID: 23451840 DOI: 10.1111/codi.12117] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2012] [Accepted: 09/29/2012] [Indexed: 12/15/2022]
Abstract
AIM Twelve to thirty % of colorectal cancer (CRC) patients and relatives with an increased familial risk of CRC are referred for preventive measures. New guidelines recommend genetic counselling for high-risk families and surveillance colonoscopy for moderate-risk families. Assessment of familial risk of CRC and referral rates for these preventive measures were determined 1 year after the introduction of new guidelines. METHOD Assessment of familial risk of CRC and referral for preventive measures were measured in clinical practice among 358 patients with CRC in 18 hospitals using medical records and questionnaires. Additionally, a knowledge survey was performed among 312 clinicians. RESULTS Sixty-seven % of patients with an increased familial risk (n = 65/97) were referred for preventive measures, as were 23% (61/261) of low-risk patients. The uptake of genetic counselling in high-risk families was 33% (12/36). The uptake of surveillance colonoscopy in moderate-risk families was 34% (21/61). In the knowledge survey clinicians correctly determined familial risk in 55% and preventive measures in 65% of cases. CONCLUSION Currently 67% of individuals with an increased familial risk of CRC were referred for preventive measures. Only one-third were referred in accordance with guidelines.
Collapse
Affiliation(s)
- N Dekker
- Scientific Institute for Quality of Healthcare, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | | | | | | | | | | |
Collapse
|
41
|
Bruwer Z, Futter M, Ramesar R. A mobile colonoscopic unit for lynch syndrome: trends in surveillance uptake and patient experiences of screening in a developing country. J Genet Couns 2013; 22:125-37. [PMID: 23299947 DOI: 10.1007/s10897-012-9523-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2011] [Accepted: 06/21/2012] [Indexed: 01/01/2023]
Abstract
The Genetic and Endoscopic Surveillance Clinic is an annual outreach service offering accessible colonoscopic surveillance to known families with Lynch syndrome living in remote areas of the Western and Northern Cape Province of South Africa. Unfortunately attendance at this outreach clinic has been declining over several years and fewer than a quarter of participants, attending for surveillance, have been adherent with all their recommended screening appointments. Concerns exist for non-adherent individuals as screening can prevent colorectal cancer by removing the precancerous lesion or enabling the treatment of a malignancy at an early stage. This study explored the experience of surveillance from both the non-adherers' and adherers' perspectives and identified unique factors affecting attendance at the outreach clinic. Rates of compliance are calculated for 191 mutation-positive cases of Lynch syndrome, using strict attendance criteria, and compared to figures obtained from self-reported attendance. Non-compliance was under-reported and compliance was exaggerated when basing data on self-reported adherence to recommendations. Specific characteristics of the outreach clinic affecting compliance are identified and recommendations are made to facilitate improvements to the service. These improvements can result in increased compliance with screening regimens and ultimately reduce cancer-related mortality.
Collapse
Affiliation(s)
- Zandrè Bruwer
- MRC/UCT Human Genetics Research Unit, Division of Human Genetics, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
| | | | | |
Collapse
|
42
|
Papanikolaou IS, Sioulas AD, Kalimeris S, Papatheodosiou P, Karabinis I, Agelopoulou O, Beintaris I, Polymeros D, Dimitriadis G, Triantafyllou K. Awareness and attitudes of Greek medical students on colorectal cancer screening. World J Gastrointest Endosc 2012; 4:513-517. [PMID: 23189223 PMCID: PMC3506969 DOI: 10.4253/wjge.v4.i11.513] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
AIM: To prospectively assess the knowledge and attitudes of medical students (MS), as tomorrow’s physicians, about colorectal cancer (CRC) and its screening modalities.
METHODS: Three hundred fourth year MS of the University of Athens were enrolled in this survey. Their selection was random, based on student identification card number. All participants completed an anonymous written questionnaire over a 4 month period. The questionnaire was divided into 4 sections and included queries about CRC-related symptoms, screening with colonoscopy and MS awareness and attitudes in this field. Following collection and analysis of the data, the results are presented as percentages of answers for each separate question.
RESULTS: Two hundred and sixty-five students answered the questionnaire over a 4 mo period. Interestingly, only 69% of the study population considered CRC to be a high-risk condition for public health. However, the vast majority of participants identified CRC-related symptoms and acknowledged its screening to be of great value in reducing CRC incidence and mortality. A very small proportion (38%) had received information material regarding CRC screening (either during their medical training or as a part of information provided to the general public) and only 60% of the participants declared willingness to receive further information. Regarding colonoscopy, 85% would prefer an alternative to colonoscopy methods for CRC screening. Moreover, 53% considered it to be a painful method and 68% would appreciate more information about the examination.
CONCLUSION: MS in Greece need to be better informed about CRC screening and screening colonoscopy.
Collapse
Affiliation(s)
- Ioannis S Papanikolaou
- Ioannis S Papanikolaou, Athanasios D Sioulas, Stylianos Kalimeris, Persephone Papatheodosiou, Ioannis Karabinis, Olga Agelopoulou, Iosif Beintaris, Dimitrios Polymeros, George Dimitriadis, Konstantinos Triantafyllou, Hepatogastroenterology Unit, 2nd Department of Internal Medicine and Research Unit, Attikon University General Hospital, Medical School, Athens University, 12462 Haidari, Greece
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Salemink S, Dekker N, Kets CM, van der Looij E, van Zelst-Stams WAG, Hoogerbrugge N. Focusing on patient needs and preferences may improve genetic counseling for colorectal cancer. J Genet Couns 2012; 22:118-24. [PMID: 22914993 PMCID: PMC3553404 DOI: 10.1007/s10897-012-9519-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2011] [Accepted: 06/14/2012] [Indexed: 12/11/2022]
Abstract
During cancer genetic counseling, different items which counselors consider important are discussed. However, relatively little empirical evidence exists regarding the needs and preferences of counselees. In this study needs and preferences were assessed from counselees with a personal and/or family history of colorectal cancer (CRC), who were referred for genetic counseling regarding CRC. They received a slightly modified version of the QUOTE-GENEca questionnaire prior to their first visit to the Hereditary Cancer Clinic. Response rate was 60 % (48/80 participants). Counselees rated the importance of 45 items assessing their needs and preferences regarding the content and process of genetic counseling. Participants rated the items regarding discussion of information about their familial CRC risk (100 %) and preventive options (98 %) as important or very important. Fewer participants rated items concerning general information on genetics as important. Sensitive communication during counseling was considered very important by a large percentage of counselees. Generally, no major differences were seen between participants in relation to individual characteristics. Our data suggest that focusing on familial CRC risk and surveillance options, in combination with sensitive communication may lead to better satisfaction with genetic counseling.
Collapse
Affiliation(s)
- Simone Salemink
- Department of Human Genetics 836, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands
| | | | | | | | | | | |
Collapse
|
44
|
Denters MJ, Deutekom M, Derkx B, Bossuyt PM, Fockens P, Dekker E. Patient satisfaction with the colonoscopy procedure: endoscopists overestimate the importance of adverse physical symptoms. Frontline Gastroenterol 2012; 3:130-136. [PMID: 28839653 PMCID: PMC5517283 DOI: 10.1136/flgastro-2012-100150] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/10/2012] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Colonoscopy is a frequently performed procedure associated with a substantial burden for the patient. Most of what is known about patient satisfaction stems from surveys that target issues doctors believe to be important. It has been noticed that patients often focus on different aspects. AIM To have patients and endoscopists rate the extent to which each of a list of patient-generated issues-of-concern contributes to patient satisfaction with the colonoscopy procedure. SUBJECTS A sample of consecutive patients undergoing colonoscopy in a Dutch tertiary teaching hospital and a convenience sample of endoscopists. METHODS Colonoscopy patients and endoscopists were asked to rate on a five-point Likert scale the importance of 55 items concerning the colonoscopy procedure for patient satisfaction. Items were derived from focus group sessions with colonoscopy patients. Endoscopists were invited to rate the importance of the same set of items from a patient perspective. An analysis was carried out of whether patients and endoscopists rated the importance of items differently. RESULTS 69 patients and 34 endoscopists completed the questionnaire. The ratings of the endoscopists were significantly different from those of patients (p<0.0001). Endoscopists underestimated the importance of involving patients in decisions, discussing risks and complications, providing the opportunity for substantive questions and offering a comfortable temperature in the examination room. Endoscopists overestimated the importance of adverse physical symptoms, such as pain and abdominal cramps, and the role of the treating doctor. CONCLUSIONS Endoscopists do not have a good perception of the items that contribute most to patient satisfaction with the colonoscopy procedure. Overcoming this gap may be an essential step towards improving patient satisfaction by targeting those concerns most relevant to patients.
Collapse
Affiliation(s)
- Maaike J Denters
- Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands
| | - Marije Deutekom
- Department of Social Medicine, Academic Medical Centre, Amsterdam, The Netherlands
| | - Bert Derkx
- Department of Pediatrics, Academic Medical Centre, Amsterdam, The Netherlands
| | - Patrick M Bossuyt
- Department of Biostatistics and Clinical Epidemiology, Academic Medical Centre, Amsterdam, The Netherlands
| | - Paul Fockens
- Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands
| | - Evelien Dekker
- Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands
| |
Collapse
|
45
|
Martínez-Ochoa E, Gómez-Acebo I, Beunza JJ, Rodríguez-Cundín P, Dierssen-Sotos T, Llorca J. Influence of Family History of Colorectal Cancer on Health Behavior and Performance of Early Detection Procedures: The SUN Project. Ann Epidemiol 2012; 22:511-9. [DOI: 10.1016/j.annepidem.2012.04.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2011] [Revised: 03/10/2012] [Accepted: 04/10/2012] [Indexed: 12/20/2022]
|
46
|
Surveillance for hereditary cancer: does the benefit outweigh the psychological burden?--A systematic review. Crit Rev Oncol Hematol 2012; 83:329-40. [PMID: 22366115 DOI: 10.1016/j.critrevonc.2012.01.004] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2011] [Revised: 12/27/2011] [Accepted: 01/25/2012] [Indexed: 12/20/2022] Open
Abstract
Individuals at risk for developing hereditary cancer are offered surveillance in order to improve the prognosis. An important question is whether the benefit of surveillance outweighs the psychological burden. In this review, we evaluated all studies that investigated psychological distress and the quality of life in individuals under surveillance for hereditary cancer of the breast, ovarian, prostate, pancreas, colorectum, melanoma, and various rare syndromes such as familial adenomatous polyposis, Li-Fraumeni and Peutz-Jeghers syndrome. Thirty-two studies were identified. Surveillance for most hereditary cancers was associated with good psychological outcomes. However, surveillance of individuals at high risk for developing multiple tumors appeared to be associated with increased distress and a lower quality of life. Common factors associated with worse psychological outcomes included a personal history of cancer, female gender, having a first degree relative with cancer, negative illness perceptions and coping style. The use of a simple screening tool to identify distressed individuals is recommended.
Collapse
|
47
|
Consedine NS, Reddig MK, Ladwig I, Broadbent EA. Gender and ethnic differences in colorectal cancer screening embarrassment and physician gender preferences. Oncol Nurs Forum 2012; 38:E409-17. [PMID: 22037340 DOI: 10.1188/11.onf.e409-e417] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
PURPOSE/OBJECTIVES To examine colorectal cancer (CRC) screening embarrassment among men and women from three ethnic groups and the associated physician gender preference by patient gender and ethnicity. DESIGN Cross-sectional, purposive sampling. SETTING Urban community in Brooklyn, NY. SAMPLE A purpose-derived, convenience sample of 245 European American, African American, and immigrant Jamaican men and women (aged 45-70 years) living in Brooklyn, NY. METHODS Participants provided demographics and completed a comprehensive measure of CRC screening embarrassment. MAIN RESEARCH VARIABLES Participant gender and ethnicity, physician gender, and CRC screening embarrassment regarding feces or the rectum and unwanted physical intimacy. FINDINGS As predicted, men and women both reported reduced fecal and rectal embarrassment and intimacy concern regarding same-gender physicians. As expected, Jamaicans reported greater embarrassment regarding feces or the rectum compared to European Americans and African Americans; however, in contrast to expectations, women reported less embarrassment than men. Interactions indicated that rectal and fecal embarrassment was particularly high among Jamaican men. CONCLUSIONS Men and women have a preference for same-gender physicians, and embarrassment regarding feces and the rectum shows the most consistent ethnic and gender variation. IMPLICATIONS FOR NURSING Discussing embarrassment and its causes, as well as providing an opportunity to choose a same-gender physician, may be promising strategies to reduce or manage embarrassment and increase CRC screening attendance.
Collapse
Affiliation(s)
- Nathan S Consedine
- Department of Psychological Medicine, University of Auckland, New Zealand.
| | | | | | | |
Collapse
|
48
|
Michaud-Herbst A, Jouhet V, Ingrand P, Letard JC, Dupuychaffray JP, Barrioz T, Beauchant M. Evaluation of French guidelines on the indications of colonoscopy: results of a regional practice survey. Clin Res Hepatol Gastroenterol 2011; 35:839-44. [PMID: 21917542 DOI: 10.1016/j.clinre.2011.07.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2011] [Accepted: 07/26/2011] [Indexed: 02/04/2023]
Abstract
BACKGROUND AND AIMS Compliance with guidelines on colonoscopic indications can improve colorectal cancer screening efficiency. We conducted a regional practice survey of gastroenterologists working in the public and private sectors in France, and compared the results with French national guidelines. METHODS Four consecutive yearly questionnaire-based practice surveys were conducted, and remedial measures were recommended on the basis of the results. RESULTS We analyzed 5128 colonoscopies carried out by 65 practitioners. Of these, 4266 (83.2%) conformed to contemporary guidelines, 391 (7.6%) did not conform, and 471 (9.2%) could not be classified, owing to a lack of information. Remedial measures led to a significant increase in the number of colonoscopies conforming to guidelines (p=0.037) and to a significant fall in the number of unclassified procedures (p=0.0018). The distribution of colonic lesions differed between procedures that did and did not conform to guidelines (2.4% versus 0.3% of colorectal cancers, 11.4% vs. 6.9% of advanced adenomas, and 17.5% vs. 14.6% of non-advanced adenomas; p<0.0001). CONCLUSION This longitudinal multicenter survey shows that national colonoscopy guidelines are largely respected in France and improve the detection of colonic neoplasia. Practices improved following implementation of remedial measures.
Collapse
Affiliation(s)
- Alban Michaud-Herbst
- Hepatogastroenterology Unit, University Hospital, 2, rue de La-Milétrie, 86000 Poitiers, France.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Harinck F, Nagtegaal T, Kluijt I, Aalfs C, Smets E, Poley JW, Wagner A, van Hooft J, Fockens P, Bruno M, Bleiker EMA. Feasibility of a pancreatic cancer surveillance program from a psychological point of view. Genet Med 2011; 13:1015-24. [DOI: 10.1097/gim.0b013e31822934f5] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
|
50
|
Colorectal cancer screening among primary care patients: does risk affect screening behavior? J Community Health 2011; 36:605-11. [PMID: 21203806 DOI: 10.1007/s10900-010-9348-0] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Lifestyle factors including smoking, obesity, and diabetes can increase colorectal cancer (CRC) risk. Controversy exists regarding screening rates in individuals at increased CRC risk. To examine the effect of risk on CRC screening in primary care, cross-sectional data collected during January 2006-July 2007 from 720 participants in 24 New Jersey primary care practices were analyzed. Participants were stratified by risk: high (personal/family history of CRC, history of polyps, inflammatory bowel disease), increased (obesity, Type II diabetes, current/former smokers), and average. Outcomes were up-to-date with CRC screening, receiving a physician recommendation for screening, and recommendation adherence. Chi-square and generalized linear modeling were used to determine the effect of independent variables on risk group and risk group on outcomes. Thirty-seven percent of participants were high-risk, 46% increased-risk, and 17% average-risk. Age, race, insurance, education, and health status were related to risk. High-risk participants had increased odds of being up-to-date with screening (OR 3.14 95% CI 1.85-5.32) and adhering to physician recommendation (OR 7.18 95% CI 3.58-14.4) compared to average-risk. Increased-risk participants had 32% decreased odds of screening (OR 0.68, 95% CI 0.42-1.08). Low screening rates among increased-risk individuals highlight the need for screening interventions targeting these patients.
Collapse
|